




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07D 233/64, 233/90, 403/10 C07D 405/14	A1	(11) International Publication Number: WO 91/00277 (43) International Publication Date: 10 January 1991 (10.01.91)
(21) International Application Number: PCT/US90/03683		(74) Agents: CHRISTENBURY, Lynne, M. et al.; E.I. du Pont de Nemours and Company, Legal Department, 1007 Market Street, Wilmington, DE 19898 (US).
(22) International Filing Date: 28 June 1990 (28.06.90)		
(30) Priority data: 373,755 30 June 1989 (30.06.89) US 544,557 27 June 1990 (27.06.90) US 545,240 27 June 1990 (27.06.90) US		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent)*, DK, DK (European patent), ES (European patent), FI, FR (European patent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU.
(71) Applicant: E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).		Published <i>With international search report.</i>
(72) Inventors: ARDECKY, Robert, John ; 607 Chambers Rock Road, Landenburg, PA 19350 (US). CARINI, David, John ; 1921 Julian Road, Wilmington, DE 19803 (US). DUNCIA, John, Jonas, Vytautas ; 35-B Martine Court, Newark, DE 19711 (US). WONG, Pancras, Chor-Bun ; 3227 Whiteman Road, Wilmington, DE 19808 (US).		

(54) Title: SUBSTITUTED IMIDAZOLES



(57) Abstract

Substituted imidazoles (I) are useful as angiotensin II blockers. These compounds have activity in treating hypertension and congestive heart failure. Pharmaceutical compositions containing the novel imidazoles and pharmaceutical compositions, alone and in conjunction with other drugs, especially diuretics and non-steroidal antiinflammatory drugs (NSAIDs) are so described.

DESIGNATIONS OF "DE"

Until further notice, any designation of "DE" in any international application whose international filing date is prior to October 3, 1990, shall have effect in the territory of the Federal Republic of Germany with the exception of the territory of the former German Democratic Republic.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MC	Monaco
AU	Australia	FI	Finland	MG	Madagascar
BB	Barbados	FR	France	ML	Mali
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Fasso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GR	Greece	NL	Netherlands
BJ	Benin	HU	Hungary	NO	Norway
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	SD	Sudan
CF	Central African Republic	KP	Democratic People's Republic of Korea	SE	Sweden
CG	Congo	KR	Republic of Korea	SN	Senegal
CH	Switzerland	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
DE	Germany, Federal Republic of	LU	Luxembourg	TG	Togo
DK	Denmark			US	United States of America

TITLE

SUBSTITUTED IMIDAZOLES

Related Application

5 This is a continuation-in-part of USSN 07/373,755,
filed June 30, 1989. Also, Carini, Duncia and Wong
U.S. application Serial No. 07/279,194, filed
December 6, 1988, discloses and claims substituted
10 imidazoles which are angiotensin II (AII) blockers and
their use, alone or in combination with other drugs, to
treat hypertension and congestive heart failure.


BACKGROUND OF THE INVENTIONField of the Invention

15 This invention relates to novel substituted
imidazoles, and processes for their preparation. The
invention also relates to pharmaceutical compositions
containing the novel imidazoles and pharmaceutical
methods using them, alone and in conjunction with other
drugs, especially diuretics and non-steroidal anti-
inflammatory drugs (NSAID's).

20 The compounds of this invention inhibit the action
of the hormone angiotensin II (AII) and are useful
therefore in alleviating angiotensin induced
hypertension. The enzyme renin acts on a blood plasma
 α_2 -globulin, angiotensinogen, to produce angiotensin I,
25 which is then converted by angiotensin converting-
enzyme to AII. The latter substance is a powerful
vasopressor agent which has been implicated as a
causitive agent for producing high blood pressure in
various mammalian species, such as the rat, dog, and
30 man. The compounds of this invention inhibit the
action of AII at its receptors on target cells and thus
prevent the increase in blood pressure produced by this
hormone-receptor interaction. By administering a
compound of this invention to a species of mammal with
35 hypertension due to AII, the blood pressure is reduced.

The compounds of this invention are also useful for the treatment of congestive heart failure. Administration of a compound of this invention with a diuretic such as furosemide or hydrochlorothiazide, either as a stepwise combined therapy (diuretic first) or as a physical mixture, enhances the antihypertensive effect of the compound. Administration of a compound of this invention with a non-steroidal anti-inflammatory drug (NSAID) can prevent renal failure which sometimes results from administration of a NSAID.

European Published Application 0 253 310, published January 20, 1988, discloses that certain substituted imidazoles block the AII receptor and are useful therefore in alleviating angiotensin induced hypertension as well as in treating congestive heart failure. The imidazoles disclosed have the formula:



30 The imidazoles of the present invention differ from those of EPA 0 253 310 in the substituents R⁷ and R⁸ at positions 4 and 5 of the imidazole ring. In EPA 0 253 310, R⁷ and R⁸ are defined as follows: R⁷ is H, F, Cl, Br, I, NO₂, CF₃ or CN; R⁸ is H, CN, alkyl of 1 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, or the same groups substituted

with F: phenylalkenyl wherein the aliphatic portion
 is 2 to 6 carbon atoms; $-(CH_2)_m$ -imidazol-1-yl;
 $-(CH_2)_m$ -1,2,3-triazolyl optionally substituted with
 one or two groups selected from CO_2CH_3 or alkyl of 1
 to 4 carbon atoms; $-(CH_2)_m$ -tetrazolyl;
 $-(CH_2)_nOR^{11}$: $-(CH_2)_nOCR^{14}$; $-(CH_2)_nSR^{15}$;
 $-\overset{R^{14}}{\underset{|}{CH}}=CH(CH_2)_s\overset{O}{\underset{|}{CH}}OR^{15}$; $-\overset{O}{\underset{|}{CH}}=CH(CH_2)_s\overset{O}{\underset{|}{CR}}^{16}$; $-\overset{O}{\underset{|}{CR}}^{16}$;
 $-\overset{O}{\underset{|}{CH}}=CH(CH_2)_sOCR^{11}$;
 $-(CH_2)_s-\overset{|}{\underset{CH_3}{CH}}-COR^{16}$; $-(CH_2)_n\overset{O}{\underset{|}{CR}}^{16}$; $-(CH_2)_n\overset{Y}{\underset{|}{OCNHR}}^{10}$;
 $-(CH_2)_n\overset{Y}{\underset{|}{NR}}^{11}\overset{O}{\underset{|}{COR}}^{10}$; $-(CH_2)_n\overset{Y}{\underset{|}{NR}}^{11}\overset{O}{\underset{|}{CNHR}}^{10}$; $-(CH_2)_n\overset{Y}{\underset{|}{NR}}^{11}SO_2R$
 $-(CH_2)_n\overset{Y}{\underset{|}{NR}}^{11}\overset{O}{\underset{|}{CR}}^{10}$, etc., where R^{10} , R^{11} , R^{14} , R^{15} , R^{16} ,

Y are as defined below for the present invention.

25 Pals et al., Circulation Research, 29, 673
(1971) describe the introduction of a sarcosine residue
in position 1 and alanine in position 8 of the
endogenous vasoconstrictor hormone AII to yield an
(octa)peptide that blocks the effects of AII on the
blood pressure of pithed rats. This analog, [Sar¹,
Ala⁸] AII, initially called "P-113" and subsequently
"Saralasin", was found to be one of the most potent
competitive antagonists of the actions of AII,
although, like most of the so-called peptide-AII-

antagonists, it also possesses agonistic actions of its own. Saralasin has been demonstrated to lower arterial pressure in mammals and man when the (elevated) pressure is dependent on circulating AII (Pals et al., 5 Circulation Research, 29, 673 (1971); Streeten and Anderson, Handbook of Hypertension, Vol. 5, Clinical Pharmacology of Antihypertensive Drugs, A. E. Doyle (Editor), Elsevier Science Publishers B.V., p. 246 (1984)). However, due to its agonistic character, 10 saralasin generally elicits pressor effects when the pressure is not sustained by AII. Being a peptide, the pharmacological effects to saralasin are relatively short-lasting and are only manifest after parenteral administration, oral doses being ineffective. Although 15 the therapeutic uses of peptide AII-blockers, like saralasin, are severely limited due to their oral ineffectiveness and short duration of action, their major utility is as a pharmaceutical standard.


Some known non-peptide antihypertensive agents 20 act by inhibiting an enzyme, called angiotensin converting enzyme (ACE), which is responsible for conversion of angiotensin I to AII. Such agents are thus referred to as ACE inhibitors, or converting enzyme inhibitors (CEI's). Captopril and enalapril are 25 commercially available CEI's. Based on experimental and clinical evidence, about 40% of hypertensive patients are non-responsive to treatment with CEI's. But when a diuretic such as furosemide or hydrochlorothiazide is given together with a CEI, the 30 blood pressure of the majority of hypertensive patients is effectively normalized. Diuretic treatment converts the non-renin dependent state in regulating blood pressure to a renin-dependent state. Although the imidazoles of this invention act by a different 35 mechanism, i.e., by blocking the AII receptor rather

than by inhibiting the angiotensin converting enzyme, both mechanisms involve interference with the renin-angiotensin cascade. A combination of the CEI enalapril maleate and the diuretic hydrochlorothiazide
5 is commercially available under the trademark Vaseretic® from Merck & Co. Publications which relate to the use of diuretics with CEI's to treat hypertension, in either a diuretic-first, stepwise approach or in physical combination, include Keeton,
10 T. K. and Campbell, W. B., Pharmacol. Rev., 31:81 (1981) and Weinberger, M. H., Medical Clinics N. America, 71:979 (1987). Diuretics have also been administered in combination with saralasin to enhance the antihypertensive effect.

15 Non-steroidal anti-inflammatory drugs (NSAID's) have been reported to induce renal failure in patients with renal underperfusion and high plasma level of AII. (Dunn, M.J., Hospital Practice, 19:99, 1984). Administration of an AII blocking compound of
20 this invention in combination with an NSAID (either stepwise or in physical combination) can prevent such renal failure. Saralasin has been shown to inhibit the renal vasoconstrictor effect of indomethacin and meclofenamate in dogs (Satoh et al., Circ. Res. 36/37 (Suppl. I):I-89, 1975; Blasingham et al., Am. J. Physiol. 239:F360, 1980). The CEI captopril has been demonstrated to reverse the renal vasoconstrictor effect of indomethacin in dogs with non-hypotensive hemorrhage. (Wong et al., J. Pharmacol. Exp. Ther.,
25 219:104, 1980).

30
35 Summary Of The Invention
According to the present invention there are provided novel compounds of formula (I) which have angiotensin II-antagonizing properties and are useful as antihypertensives.


6



wherein


15

R^1 is $4-CO_2H$; $4-CO_2R^9$; $-O-S(=O)(=O)-OH$; $-SO_3H$;




20


$4-NHSO_2CH_3$; $4-NHSO_2CF_3$; $-CONHOR^{12}$;




30



35





20 R² is H; Cl; Br; I; F; NO₂; CN; alkyl of 1 to 4 carbon atoms;
acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms;
CO₂H; CO₂R⁹; NHSO₂CH₃; NHSO₂CF₃;

25 CONHOR¹²; SO₂NH₂;  ; aryl; or furyl;

R^3 is H; Cl, Br, I or F; alkyl of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms;

R^4 is CN, NO₂ or CO₂R¹¹;

30 R⁵ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms alkenyl or alkynyl of 2 to 4 carbon atoms;

³⁵ R⁶ is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl of 3 to 10 carbon atoms or the same groups substituted with F or CO₂R¹⁴; cycloalkyl of 3 to 8 carbon atoms, cycloalkylalkyl of 4 to 10 carbon atoms; cycloalkylalkenyl or cycloalkylalkynyl

of 5 to 10 carbon atoms; $(\text{CH}_2)_5\text{Z}(\text{CH}_2)_m\text{R}^5$ optionally substituted with F or CO_2R^{14} ; benzyl or benzyl substituted on the phenyl ring with 1 or 2 halogens, alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4 carbon atoms or nitro;

- 5 R^7 is vinyl; cycloalkylideny; alkynyl of 2-10 carbon atoms; phenylalkynyl where the alkynyl portion is 2-6 carbon atoms; heteroaryl selected from 2- and 3-thienyl, 2- and 3-furyl, 2-, 3-, and 4-pyridyl, 2-pyrazinyl, 2-, 4-, and 5-pyrimidinyl, 3- and 4-pyridazinyl, 2-, 4- and 5-thiazolyl, 2-, 4-, and 10 5-selenazolyl, and 2-, 4-, and 5-oxazolyl, 2- or 3-pyrrolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-imidazolyl; o-, m- or p-biphenylyl; o-, m- or p-phenoxyphenyl; 2-oxazolinyl; 2-thiazolinyl; substituted phenylalkynyl, heteroaryl, biphenylyl or phenoxyphenyl as defined above substituted with 15 1 or 2 substituents selected from halogen, hydroxy, mercapto, alkoxy of 1-5 carbon atoms, alkyl of 1-5 carbon atoms, $-\text{NO}_2$, $-\text{CN}$, $-\text{CF}_3$, $-\text{COR}^{16}$, $-\text{CH}_2\text{OR}^{17}$, $-\text{NHCOR}^{17}$, $-\text{CONR}^{18}\text{R}^{19}$, $\text{S}(\text{O})_r\text{R}^{17}$, and $\text{SO}_2\text{NR}^{18}\text{R}^{19}$; pyrrolyl, pyrazolyl or imidazolyl as defined above substituted on ring nitrogen with alkyl of 1-5 carbon atoms, phenyl or benzyl; or substituted alkyl, alkenyl, or alkynyl of 1 to 10 carbon atoms substituted with a substituted or unsubstituted heteroaryl, biphenylyl or phenoxyphenyl group as defined above; $-\text{S}(\text{O})_r$ -heteroaryl, $-\text{S}-(\text{O})_r$ -biphenylyl, $-\text{S}(\text{O})_r$ -phenoxyphenyl, $-\text{S}$ -tetrazole, $-\text{S}(\text{O})_r\text{R}^{17}$, $-\text{NR}^{18}\text{R}^{19}$, 20 $-\text{NR}^{18}$ -heteroaryl, $-\text{NR}^{18}$ -phenyl, $-\text{NR}^{18}$ -biphenylyl, $-\text{NR}^{18}$ -phenoxyphenyl, $-\text{N}$ -phthalimido, $-\text{NH-SO}_2$ -phenoxyphenyl, $-\text{NH-SO}_2$ -heteroaryl, $-\text{NH-SO}_2$ -biphenylyl, $-\text{NH-SO}_2\text{R}^{17}$, and $-\text{S}-(\text{C=O})-\text{R}^{17}$, N-imidazolyl, N-1,2,3-triazolyl, N-1,2,4-triazolyl, 25 where heteroaryl is a heterocycle defined in the scope of R^7 and where the phenyl group in R^{17} of $-\text{S}-(\text{O})_r\text{R}^{17}$, the N-imidazolyl, N-1,2,3-triazolyl, and N-1,2,4-triazolyls may be substituted with one or two substituents as described above for heteroaryl;

9

R^8 is $-(CH_2)_{n-1}CH-$ R^{11} ; $-(CH_2)_nO$ CR^{14} ; $-(CH_2)_nSR^{15}$;

$\overset{0}{\underset{OR^{17}}{|}}$

5 $\overset{R^{14}}{\underset{|}{-CH=CH(CH_2)_sCHOR^{15}}}; \overset{0}{-CH=CH(CH_2)_sCR^{16}}; \overset{0}{-CR^{16}};$

10 $\overset{0}{-CH=CH(CH_2)_sOCR^{11}}; -(CH_2)_m$ -tetrazolyl;

15 $(CH_2)_s-CH-$ COR^{16} ; $-(CH_2)_n$ $\overset{0}{CR^{16}}$; $-(CH_2)_n$ $\overset{Y}{OCNHR^{10}}$;

$\overset{CH_3}{|}$

20 $-(CH_2)_n$ $\overset{Y}{NR^{11}}COR^{10}$; $-(CH_2)_n$ $\overset{0}{NR^{11}}CNHR^{10}$; $-(CH_2)_n$ $\overset{Y}{NR^{11}}SO_2R^{10}$;

$\overset{Y}{|}$

$-(CH_2)_n$ $\overset{Y}{NR^{11}}CR^{10}$;

25 R^9 is $\overset{R^{24}}{\underset{|}{-CH-OCR^{21}}};$

R^{10} is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or $(CH_2)_pC_6H_5$;

30 R^{11} is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R^{12} is H, methyl or benzyl;


R^{13} is $-CO_2H$; $-CO_2R^9$; $-CH_2CO_2H$, $-CH_2CO_2R^9$;

35 $\overset{0}{-O-S-OH}; \overset{0}{-O-P(OH)_2}; \overset{0}{-SO_3H}; \overset{0}{-NHP-OH}$

$\overset{||}{O} \quad \overset{|}{OH} \quad \overset{|}{OH}$



$-PO_3H_2$; $-C(CF_3)_2OH$; $-HSO_2CH_3$; $-HSO_2CF_3$; $-HCOCF_3$;

$-CONHOR^{12}$; $-SO_2NH_2$; $\begin{array}{c} OH \\ | \\ -C-P(OH)_2 \\ | \\ R^{27} \\ | \\ OH \end{array}$



SUBSTITUTE SHEET

SUBSTITUTE SHEET



10 R¹⁴ is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R¹⁵ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4

15 carbon atoms, phenacyl:

R¹⁶ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH₂)_nC₆H₅, OR¹⁷, or NR¹⁸R¹⁹.

R¹⁷ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

20 R¹⁸ and R¹⁹ independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, α -methylbenzyl, or taken together with the nitrogen form a ring of the formula

25 

Q 1s NR²⁰, O or CH₂;

R^{20} is H, alkyl of 1-4 carbon atoms, or phenyl:

R²¹ is alkyl of 1 to 6 carbon atoms, -NR²²R²³.

30 or $-\text{CHCH}_2\text{CO}_2\text{CH}_3$;
 $\begin{array}{c} | \\ \text{NH}_2 \end{array}$


R²² and R²³ independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH₂)_u where u = 2, 3, 4, 5, 6.

35 u is 3-6;
R²⁴ is H, CH₃ or -C₆H₅;

SUBSTITUTE SHEET

SUBSTITUTE SHEET

R²⁵ is NR²⁷R²⁸, OR²⁸, NHCONH₂, NHCSNH₂,



5 R²⁶ is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R²⁷ and R²⁸ are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

10 R²⁹ and R³⁰ are independently alkyl of 1-4 carbon atoms or taken together are -(CH₂)_q-;

R³¹ is H, alkyl of 1 to 4 carbon atoms, -CH₂CH=CH₂ or -CH₂C₆H₄R³²;

R³² is H, NO₂, NH₂, OH or OCH₃;

X is a carbon-carbon single bond, -CO-, -CH₂-, -O-, -S-,

15 -NH-, -N- , -CON- , -NCO-, -OCH₂-, -CH₂O-,
R²⁶ R²³ R²³

-SCH₂-, -CH₂S-, -NHC(R²⁷)(R²⁸), -NR²³SO₂-,
-SO₂NR²³-, -C(R²⁷)(R²⁸)NH-, -CH=CH-, -CF=CF-,

20 -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-,

25 OR¹⁴ OCOR¹⁷ NR²⁵ R²⁹O / OR³⁰
-CH- , -CH- , -C- or -C- ;

Y is O or S;

Z is O, NR¹¹, or S;

m is 1 to 5;

n is 1 to 10;

p is 0 to 3;

30 q is 2 to 3;

r is 0 to 2;

s is 0 to 5;

t is 0 or 1;

and pharmaceutically acceptable salts of these compounds;


provided that:

(1) the R¹ group is not in the ortho position;

5

(2) when R¹ is -X- X is a single bond,

10

and R¹³ is CO₂H, or , then R¹³ must

15

be in the ortho or meta position; or when R¹ and X are as above and R¹³ is NHSO₂CF₃ or NHSO₂CH₃, R¹³ must be ortho;

20

(3) when R¹ is -X- and X is other than

25

a single bond, then R¹³ must be ortho except when X = NR²³CO and R¹³ is NHSO₂CF₃ or NHSO₂CH₃, then R¹³ must be ortho or meta;

25

(4) when R¹ is 4-CO₂H or a salt thereof, R⁶ cannot be S-alkyl;

25

(5) when R¹ is 4-CO₂H or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH₂OH, CH₂OCOCH₃, or CH₂CO₂H;

30

(6) when R¹ is -NHCO-, R⁶ is not methoxybenzyl;


35

13

5

Preferred for their antihypertensive activity are novel compounds having the formula:


10



15

wherein

20



25


R^6 is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, benzyl substituted on the phenyl ring with up to two groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro:

R^8 is $-(CH_2)_m\text{-tetrazolyl}$, $-(CH_2)_nOR^{11}$; $-(CH_2)_nO\overset{O}{C}R^{14}$;


35

SUBSTITUTE SHEET

14



5

R^{13} is $-\text{CO}_2\text{H}$, $-\text{CO}_2\text{R}^9$, NHSO_2CF_3 ; SO_3H ; or 

10

R^{16} is H, alkyl of 1 to 5 carbon atoms, OR^{17} , or $\text{NR}^{18}\text{R}^{19}$;

X is carbon-carbon single bond, $-\text{CO}-$, $-\text{CON}-$,

$\begin{array}{c} | \\ \text{R}^{23} \end{array}$

15

$-\text{CH}_2\text{CH}_2-$, $-\text{NCO}-$, $-\text{OCH}_2-$, $-\text{CH}_2\text{O}-$, $-\text{SCH}_2-$,

$\begin{array}{c} | \\ \text{R}^{23} \end{array}$

$-\text{CH}_2\text{S}-$, $-\text{NHCH}_2-$, $-\text{CH}_2\text{NH-}$ or $-\text{CH}=\text{CH-}$; and

20

pharmaceutically acceptable salts of these compounds.

More preferred are compounds of the preferred scope where:

R^2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;

25

R^6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;

R^7 is heteroaryl selected from 2- and 3-thienyl, 2- and 3-furyl, 2-, 3-, and 4-pyridyl, or p-biphenyl,


30




35

R^8 is $-(CH_2)_mOR^{11}$; $-(CH_2)_m\overset{O}{C}R^{14}$; $-\overset{R^{14}}{CH=CH-CHOR^{15}}$;
 5 $-(CH_2)_m\overset{O}{CR^{16}}$; $-\overset{O}{CH_2NHCOR^{10}}$;
 $-(CH_2)_mNHSO_2R^{10}$; or $-COR^{16}$;

R^{10} is CF_3 , alkyl of 1 to 6 carbon atoms or phenyl;
 R^{11} is H, or alkyl of 1 to 4 carbon atoms;
 10 R^{13} is CO_2H ; $CO_2CH_2OCOC(CH_3)_3$; $NHSO_2CF_3$



15 R^{14} is H, or alkyl of 1 to 4 carbon atoms;
 R^{15} is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to
 4 carbon atoms;
 R^{16} is H, alkyl of 1 to 5 carbon atoms; OR^{17} ; or



m is 1 to 5;
 X = single bond, $-O-$; $-CO-$; $-NHCO-$; or $-OCH_2-$; and
 25 pharmaceutically acceptable salts.

Note that throughout the text when an alkyl substituent is mentioned, the normal alkyl structure is meant (i.e., butyl is *n*-butyl) unless otherwise specified.

30 Pharmaceutically suitable salts include both the metallic (inorganic) salts and organic salts; a list of which is given in Remington's Pharmaceutical Sciences, 17th Edition, pg. 1418 (1985). It is well known to one skilled in the art that an appropriate salt form is chosen based on physical and chemical stability,

SUBSTITUTE SHEET

SUBSTITUTE SHEET

flowability, hydroscopicity and solubility. Preferred salts of this invention for the reasons cited above include potassium, sodium, calcium and ammonium salts.

Also within the scope of this invention are pharmaceutical compositions comprising a suitable pharmaceutical carrier and a compound of Formula (I), and methods of using the compounds of Formula (I) to treat hypertension and congestive heart failure. The pharmaceutical compositions can optionally contain one or more other therapeutic agents, such as a diuretic or a non-steroidal antiinflammatory drug. Also within the scope of this invention is a method of preventing renal failure resulting from administration of a non-steroidal antiinflammatory drug (NSAID) which comprises administering a compound of Formula (I) in stepwise or physical combination with the NSAID. The compounds of this invention can also be used as diagnostic agents to test the renin angiotensin system.

It should be noted in the foregoing structural formula, when a radical can be a substituent in more than one previously defined radical, that first radical can be selected independently in each previously defined radical. For example, R¹, R² and R³ can each be CONHOR¹². R¹² need not be the same substituent in each of R¹, R² and R³ but can be selected independently for each of them.

Detailed Description

Synthesis

The novel compounds of Formula (I) may be prepared using the reactions and techniques described in this section. The reactions are performed in a solvent appropriate to the reagents and materials employed and suitable for the transformation being effected. It is understood by those skilled in the art of organic

SUBSTITUTE SHEET

SUBSTITUTE SHEET

17

synthesis that the functionality present on the imidazole and other portions of the molecule must be consistent with the chemical transformations proposed. This will frequently necessitate judgment as to the 5 order of synthetic steps, protecting groups required, deprotection conditions, and activation of a benzylic position to enable attachment to nitrogen on the imidazole nucleus. Throughout the following section, not all compounds of Formula (I) falling into a given 10 class may necessarily be prepared by all methods described for that class. Substituents on the starting materials may be incompatible with some of the reaction conditions required in some of the methods described. Such restrictions to the substituents which are 15 compatible with the reaction conditions will be readily apparent to one skilled in the art and alternative methods described must then be used.


20

25

30

35

SUBSTITUTE SHEET

Scheme 1

SUBSTITUTE SHEET

Generally, compounds of Formula (3) can be prepared by direct alkylation onto imidazole (1), with an appropriately protected benzyl halide, tosylate or mesylate (2) in the presence of base, as shown in path 5 a). Preferably, the metallic imidazolide salt is prepared by reacting imidazole (1) with a proton acceptor such as MH where M is lithium, sodium or potassium in a solvent such as dimethylformamide (DMF) or by reacting it with a metal alkoxide of formula MOR 10 where R is methyl, ethyl, t-butyl or the like in an alcohol solvent such as ethanol or t-butanol, or a dipolar aprotic solvent such as dimethylformamide. The imidazole salt is dissolved in an inert aprotic solvent such as DMF, and treated with an appropriate alkylating 15 agent (2). Alternatively, imidazole (1) can be alkylated with a benzyl halide (2, where X=Br, Cl) in the presence of a base such as sodium carbonate, potassium carbonate, triethylamine or pyridine. The reaction is run in an inert solvent such as DMF or DMSO 20 at 20°C to the reflux temperature of the solvent for 1-10 hours.

For example, the 4-nitrobenzyl intermediate (3a, wherein R¹ = 4-NO₂, R² = R³ = H) may be obtained by direct alkylation onto imidazole (1) with a 25 4-nitrobenzyl halide, tosylate or mesylate in the presence of base.

As R⁷ and R⁸ are different, mixtures of two regioisomer alkylation products (3b, and 3c) are obtained in which R⁷ and R⁸ are interchanged. When R⁸ 30 is CHO the alkylation is such that the benzyl group becomes attached to the adjacent nitrogen preferentially. These isomers possess distinct physical and biological properties and can usually be separated and isolated by conventional separation 35 techniques such as chromatography and/or crystallization.

In all series examined, the more rapidly eluted isomer of a given pair has greater biological potency than the less rapidly eluted isomer.

Alternatively, any properly functionalized benzylamine derivative (4) may be converted to imine (6) by treatment with an acylamino ketone (5) in the presence of an inert solvent such as benzene, toluene, or the like, and a catalytic amount of p-toluene-sulfonic acid or molecular sieves, N. Engel, and W. Steglich, Liebigs Ann. Chem., 1916, (1978), or in the presence of alumina, F. Texier-Boulet, Synthesis, 679 (1985). The resulting imine (6) can be cyclized to the N-benzyl imidazole (3) with phosphorus pentachloride (PCl_5), phosphorus oxychloride ($POCl_3$) or triphenylphosphine (PPh_3) in dichloroethane in the presence of a base such as triethylamine, N. Engel and W. Steglich, Liebigs Ann. Chem., 1916, (1978).

Acylamino ketone (5) is readily obtainable from amino acids via the Dakin-West reaction, H.D. Dakin, R. West, J. Biol. Chem., 78, 95 and 745 (1928), and various modifications thereof, W. Steglich, G. Hofle, Angew. Chem. Int. Ed. Engl., 8, 981 (1969); G. Hofle, W. Steglich, H. Vorbruggen, Angew. Chem. Int. Ed. Engl., 17, 569 (1978); W. Steglich, G. Hofle, Ber., 102, 883 (1969), or by selective reduction of acyl cyanides, A. Pfaltz, S. Anwar, Tet. Lett. 2977 (1984), or from α -halo, α -tosyl or α -mesyl ketones via the appropriate substitution reactions that one skilled in the art will readily recognize.

The functionalized benzylamines (4) may be made from the corresponding benzyl halide, tosylate or mesylate (2) via displacement with a nitrogen nucleophile, a procedure familiar to one skilled in the art. This displacement may be achieved using azide ion, ammonia, or phthalimide anion, etc., in a neutral

solvent such as dimethylformamide, dimethylsulfoxide etc., or under phase transfer conditions. The benzyl halide (2) may be made by a variety of benzylic halogenation methods familiar to one skilled in the art,

5 for example benzylic bromination of toluene derivatives with N-bromosuccinimide in an inert solvent such as carbon tetrachloride in the presence of a radical initiator such as benzoyl peroxide at temperatures up to reflux conditions.

10 A wide variety of toluene derivatives may be made from simple electrophilic substitution reactions on an aromatic ring. This includes nitration, sulfonation, phosphorylation, Friedel-Crafts alkylation, Friedel-Crafts acylation, halogenation, and
15 other similar reactions known to one skilled in the art, G. A. Olah, "Friedel-Crafts and Related Reactions," Vol. 1-5, Interscience, New York, (1965).

Another way to synthesize functionalized benzyl halides is via chloromethylation of the
20 corresponding aromatic precursor. Thus, the appropriately substituted benzene ring may be chloromethylated with formaldehyde and hydrochloric acid (HCl) for example with or without an inert solvent such as chloroform, carbon tetrachloride, light petroleum ether or acetic acid. A Lewis acid such as
25 zinc chloride ($ZnCl_2$) or a mineral acid such as phosphoric acid may also be added as a catalyst or condensing agent, R. C. Fuson, C. H. McKeever, Org. Reactions, 1, 63 (1942).

30 Alternatively, N-benzylimidazoles (3) can also be prepared as shown in path b) by forming an R^6 substituted amidine (7) from an appropriately substituted benzylamine (4) which is in turn reacted with an α -haloketone, α -hydroxyketone (8), α -haloaldehyde, or

α -hydroxyaldehyde, F. Kunckell, Ber., 34, 637 (1901).

As shown in path a), imidazole (1) may be alkylated by a variety of benzyl derivatives. These 5 include compounds with latent acid functionalities such as o, m, and p-cyanobenzylhalides, mesylates or tosylates as shown in path c). Nitriles of formula (9) may be hydrolyzed to carboxylic acids of formula (10) by treatment with strong acid or alkali. Preferably, 10 treatment with a 1:1 (v/v) mixture of concentrated aqueous hydrochloric acid/glacial acetic acid at reflux temperatures for 2-96 hours or by treatment with 1N sodium hydroxide in an alcohol solvent such as ethanol or ethylene glycol for 2-96 hours at temperatures from 15 20°C to reflux can be used. If another nitrile group is present it will also be hydrolyzed. The nitrile functionality can also be hydrolyzed in two steps by first stirring in sulfuric acid to form the amide followed by hydrolysis with sodium hydroxide or a mineral acid to give the carboxylic acid (10).

The nitriles (9) can be converted into the corresponding tetrazole derivative (11) by a variety of methods using hydrazoic acid. For example, the nitrile can be heated with sodium azide and ammonium chloride 25 in DMF at temperatures between 30°C and reflux for 1-10 days, J. P. Hurwitz and A. J. Tomson, J. Org. Chem., 26, 3392 (1961). Preferably, the tetrazole is prepared by the 1,3-dipolar cycloaddition of trialkyltin or triaryltin azides to the appropriately substituted 30 nitrile as described in detail by Scheme 15.

The starting imidazole compounds (1) are readily available by any of a number of standard methods. For example, acylaminoketone (5) can be cyclized with ammonia or equivalents thereof, D. 35 Davidson, et al., J. Org. Chem., 2, 319 (1937) to the

corresponding imidazole as shown in Scheme 1. The corresponding oxazole can also be converted to imidazole (1) by action of ammonia or amines in general, H. Bredereck, et al., Ber., 88, 1351 (1955);
5 J. W. Cornforth and R. H. Cornforth, J. Chem Soc., 96, (1947).

Several alternative routes to imidazoles (1) are illustrated in Scheme 2. As shown in Scheme 2 equation a), reaction of the appropriate R^6 substituted 10 imidate esters (12) with an appropriately substituted α -hydroxy- or α -haloketone or aldehyde (8) in ammonia leads to imidazoles of formula (1), P. Dziuron, and W. Schunack, Archiv. Pharmaz., 307 and 470 (1974).

The starting imidazole compounds (1) wherein 15 R^7 and R^8 are both hydrogen can be prepared as shown in equation b) by reaction of the appropriate R^6 -substituted imidate ester (12) with α -aminoacetaldehyde dimethyl acetal (13), M. R. Grimmett, Adv. Heterocyclic Chem., 12, 103 (1970).

20 As shown in equation c), imidazole (15; wherein R^7 = hydrogen and R^8 = CH_2OH) can be prepared by treatment of the imidate ester (12) with 1,3-dihydroxyacetone (14) in ammonia by the procedure described in Archive der Pharmazie, 307, 470 (1974).

25 Halogenation of imidazole (15) or any imidazole wherein R^7 or R^8 is hydrogen is preferably accomplished by reaction with one to two equivalents of N-halosuccinimide in a polar solvent such as dioxane or 2-methoxyethanol at a temperature of 40-100°C for 1-10 hours. Reaction of the halogenated imidazole (16) with 30 a benzylhalide (2) in the manner described in Scheme 1 affords the corresponding N-benzylimidazole (17); wherein R^7 is halogen and R^8 is CH_2OH). This procedure is described in U.S. Patent 4,355,040. Alternatively,

24

imidazole (17) can be prepared by the procedure described in U.S. Patent 4,207,324.

Compounds of formula (17) can also be prepared by treatment of the starting imidazole compound (1) wherein R⁷ and R⁸ are both hydrogen, with the appropriate benzyl halide followed by functionalization of R⁷ and R⁸ by treatment with formaldehyde as described in E. F. Godefroi, et al., Recueil, 91, 1383 (1972) followed by halogenation as was described above.

As shown in equation d) the imidazoles (1) can also be prepared by reaction of R⁶ substituted amidines (18) with an α -hydroxy- or α -haloketone or aldehyde (8) as described by F. Kunckel, Ber., 34, 637, (1901).

Compounds of Formula (1) wherein R⁸= CH₂OH can be prepared as shown in equation e). The imidazoles (1) were prepared as described in L. A. Reiter, J. Org. Chem., 52, 2714 (1987). Hydroxymethylation of (1) as described by U. Kempe, et al. in U.S. Patent 4,278,801 provides the hydroxymethylimidazoles (1a).





20

25

30

35


SUBSTITUTE SHEET

Scheme 2



SUBSTITUTE SHEET

Scheme 2 (continued)

5



10



15

la


20

25

30

35

SUBSTITUTE SHEET

Scheme 3

SUBSTITUTE SHEET

As shown in Scheme 3, path a) for benzylimidazoles (17) where R⁸ = CH₂OH, the hydroxymethyl groups may be easily converted to the corresponding halide, mesylate or tosylate by a variety of methods familiar to one skilled in the art.

5 Preferably, the alcohol (17) is converted to the chloride (25) with thionyl chloride in an inert solvent at temperatures of 20°C to the reflux temperature of the solvent.

10 Chloride (25) may be displaced by a variety of nucleophiles by nucleophilic displacement reaction procedures familiar to one skilled in the art. For example, excess sodium cyanide in DMSO may be used to form cyanomethyl derivatives (26) at temperatures of 15 20°C to 100°C.

20 Nitrile (26) may be hydrolyzed to an acetic acid derivative (27), by a variety of methods. These methods include methods described previously for the hydrolysis of nitriles of formula (9). Examples of desired acids and bases for this hydrolysis include mineral acids such as sulfuric acid, hydrochloric acid, and mixtures of either of the above with 30-50% acetic acid (when solubility is a problem), and alkali metal hydroxides such as sodium hydroxide or potassium hydroxide. The hydrolysis reaction proceeds under heating at temperatures ranging from 50-160°C for 2-48 hours. Carboxylic acid (27) may be esterified by a variety of methods without affecting other parts of the molecule. Preferably, (27) is refluxed in a 25 hydrochloric acid/methanol solution for 2-48 hours to give ester (28).

30 Ester (28) may be hydrolyzed to carboxylic acid (27), for instance, after R¹, R² and R³ have been elaborated. Various methods, acidic or basic, may be used. For example, compound (28) is stirred with 0.5N

potassium hydroxide in methanol, or if base soluble, it is stirred in 1.0N sodium hydroxide for 1-48 h at 20°C to reflux temperatures.

Hydroxymethyl derivative (17) may be acylated
5 to give (29) by a variety of procedures. As shown in path b) acylation can be achieved with 1-3 equivalents of an acyl halide or an anhydride in a solvent such as diethyl ether, tetrahydrofuran, methylene chloride or the like in the presence of a base such as pyridine or
10 triethylamine. Alternatively (17) may be acylated by reaction with a carboxylic acid and dicyclohexylcarbodiimide (DCC) in the presence of a catalytic amount of 4-(N,N-dimethylamino)pyridine (DMAP) via the procedure described by A. Hassner, *Tet. Lett.*, **46**, 4475 (1978).
15 Treatment of (17) with a solution of carboxylic acid anhydride in pyridine optionally with a catalytic amount of DMAP at temperatures of 20-100°C for 2-48 hours is the preferred method.

The ether (30) can be prepared from the
20 alcohol (17) as shown in path c) by methods such as treatment of (17) in a solvent such as dimethylformamide or dimethylsulfoxide with potassium t-butoxide, sodium hydride, or the like followed by treatment with R¹¹L at 25°C for 1-20 hours, where L is
25 a halogen, tosylate or mesylate.

Alternatively, treatment of (17) with 1-5 equivalents of thionyl chloride in chloroform for 2-6 hours at 25°C followed by treatment of the intermediate (25) with 1-3 equivalents of MOR¹¹, where M is sodium or potassium, for 2-10 hours at 25°C either in R¹¹OH as
30 solvent or in a polar solvent such as dimethylformamide or the like will also yield ether (30).

The ether (30) can also be prepared for example by heating (17) for 3-15 hours at 60-160°C in


$R^{11}OH$ containing an inorganic acid such as a hydrochloric acid or sulfuric acid.

N-arylimidazoles of formula I (compounds wherein $r=0$) can be prepared by the following methods, 5 it being understood by one skilled in the art that certain manipulations, protecting and deprotecting steps, and other synthetic procedures disclosed above may be necessary to produce compounds with the desired combinations of R^6 , R^7 , R^8 and R^{13} .

10 As shown in Scheme 4, equation a) the reaction of aniline derivative (34) with imidate ester (12) to form the substituted amidine (35) provides material which can be cyclized with dihydroxyacetone to form structure (36). Subsequent elaboration into (I) 15 provides the N-arylimidazole compounds of the invention.


Alternatively as shown by equation b) the Marckwald procedure, described by Marckwald et al., Ber., 22, 568, 1353 (1889); Ber., 25, 2354 (1892) can 20 form a 2-mercaptoimidazole (38) from aniline derivative (34) via isothiocyanate (37). Desulfurization of (38) with dilute nitric acid followed by anion formation at the 2-position of the imidazole (39) and reaction with R^6X where X is Cl, Br, I, allows the formation of (40) 25 which can be subsequently elaborated to I.

A variation of Marckwald's process as shown in equation c) using an α -aminoketone (41) and isothiocyanate (37) can also be employed, see Norris and McKee, J. Amer. Chem. Soc., 77, 1056 (1955) can 30 also be employed. Intermediate (42) can be converted to (I) by known sequences. The general procedure of Carboni et al., J. Amer. Chem. Soc., 89, 2626 (1967) (illustrated by equation d)) can also be used to prepare N-aryl substituted imidazoles from appropriate 35 haloaromatic compounds (43; X=F, Cl, Br) and imidazoles (1):

Scheme 4

32


Scheme 4 (continued)



SUBSTITUTE SHEET

In various synthetic routes R¹, R² and R³ do
not necessarily remain the same from the starting
compound to the final products, but are often
manipulated through known reactions in the intermediate
5 steps as shown in Schemes 5-22. All of the
transformations shown in Schemes 5-10 and 12 can also
be carried out on the terminal aromatic ring (i.e.,
biphenyl ring).

10

Scheme 5

As shown in Scheme 5, compounds where R¹ is a
sulfonic acid group may be prepared by oxidation of the
corresponding thiol (45). Thus, an N-benzylimidazole
derivative bearing a thiol group may be converted into
a sulfonic acid (46) by the action of hydrogen
peroxide, peroxyacids such as metachloroperoxybenzoic
acid, potassium permanganate or by a variety of other
oxidizing agents, E. E. Reid, Organic Chemistry of
Bivalent Sulfur, 1, Chemical Publishing Co., New York,
120-121 (1958).

35 Aromatic hydroxy or thiol groups are obtained
from deprotection of the corresponding alkyl ether or
thioethers. Thus, for example, a methyl ether or a

methyl thioether derivative (44) of an N-benzylimidazole containing one or more aromatic rings may be converted into the free phenol or thiophenol (45) by the action of boron tribromide methyl sulfide, P. G. Willard and C. F. Fryhle, Tet. Lett., 21, 3731 (1980); trimethylsilyl iodide, M. E. Jung and M. A. Lyster, J. Org. Chem., 42, 3761 (1977); KSET and derivatives thereof, G. I. Feutrill, R. N. Mirrington, Tet. Lett., 1327, (1970), and a variety of other reagents.

10 Alternatively, N-benzylimidazoles may be sulfonated by stirring with H_2SO_4 at a variety of different concentrations or with other sulfonating agents such as chlorosulfonic acid or sulfur trioxide with or without complexing agents such as dioxane or
15 pyridine at temperatures from 0 to 200°C with or without solvent, K. LeRoi Nelson in Friedel-Crafts and Related Reactions, III part 2, G. A. Olah, ed., Interscience Publ., 1355 (1964).


20 The synthesis of compounds where R^1 is a sulfate, phosphate or phosphonic acid are depicted in Scheme 6:

25


30

35

Scheme 6



Scheme 6 (continued)



SUBSTITUTE SHEET

N-Benzylimidazoles containing a phenolic hydroxyl group (47) may be readily converted into the corresponding sulfate (48) or phosphate (49). As shown in equation a), reaction of the phenol with a sulfur trioxide-amine complex will give the corresponding sulfate (48), E. E. Gilbert, Sulfonation and Related Reactions, Interscience, New York, chapter 6 (1965). Reaction of the phenol (47) with phosphorus pentachloride followed by hydrolysis will give the corresponding phosphate (49), G. M. Kosolapoff, Organophosphorus Compounds, John Wiley, New York, 235 (1950).

As shown in equation b) N-benzylimidazoles may be converted into the corresponding phosphonic acids by reaction with phosphorus trichloride (PCl_3) and aluminum chloride (AlCl_3) in an inert solvent for 0.5-96 hours from temperatures of 25°C to the reflux temperatures of the solvent. Appropriate workup followed by reaction with chlorine (Cl_2) and subsequent hydrolysis of the tetrachloride (51) gives the phosphonic acid derivative (52), G. M. Kosolapoff in Org. Reactions, 6, R. Adams, editor, John Wiley and Sons, New York, 297 (1951). Another more direct route involves reaction of the N-benzylimidazole with PSCl_3 and AlCl_3 followed by hydrolysis, R. S. Edmunson in Comprehensive Organic Chemistry, Vol. 2, D. Barton and W. D. Ollis editors, Pergamon Press, New York, 1285 (1979).


Alternatively, equation c) illustrates that aryl phosphonic acids (52) may be formed from reaction of the corresponding diazonium salt (53) with PCl_3 in the presence of Cu(I) followed by hydrolysis with water (ibid, p. 1286).

As shown in equation d), the aryl halides (55) may be photolyzed in the presence of phosphite esters

to give phosphonate esters (56), R. Kluger, J. L. W. Chan, J. Am. Chem. Soc., 95, 2362, (1973). These same aryl halides also react with phosphite esters in the presence of nickel or palladium salts to give
 5 phosphonate esters, P. Tavs, Chem. Ber., 103, 2428 (1970), which can be subsequently converted to phosphonic acids (52) by procedures known to one skilled in the art.

10 N-Benzylimidazoles containing an aldehyde or ketone (57) may be reacted with a phosphorus trihalide followed by water hydrolysis to give α -hydroxyphosphonic acid derivatives, G.M. Kosolapoff, op. cit., 304, as shown in Scheme 7.



15

Scheme 7

30

35

Compounds where R¹ is -CONHOR¹² may be prepared as shown in Scheme 8, by the treatment of a carboxylic acid (10) with 1-4 equivalents of thionyl chloride for 1-10 hours. This reaction can be run without solvent or in a nonreactive solvent such as benzene or chloroform at temperatures of 25-65°C. The intermediate acid chloride is then treated with 2-10 equivalents of the appropriate amine derivative, H₂N-OR¹², for 2-18 hours at temperatures of 25-80°C in a polar aprotic solvent such as tetrahydrofuran or dimethylsulfoxide to give the hydroxamic acid (59).

Scheme 8

Alternatively, the carboxylic acid (10) can be converted to the hydroxamic acid (59) according to the procedure in J. Med. Chem., 28, 1158 (1985) by employing dicyclohexylcarbodiimide, 1-hydroxybenzo-

triazole, and $\text{H}_2\text{NOR}^{12}$ or according to the procedure described in Synthesis, 929 (1985) employing the Vilsmeier reagent and $\text{H}_2\text{NOR}^{12}$.

Compounds where R^1 is $-\text{CONHSO}_2\text{Ar}$ (59a, 5 $\text{Ar}=\text{phenyl, o-tolyl, etc.}$) may be produced by treatment of the intermediate acid chlorides from the preparation of the hydroxamic acids (59), with ArSO_2NHNa . Alternatively, these acylsulfonamides (59a) can be prepared from the carboxylic acids (10) through the 10 corresponding $\text{N,N-diphenylcarbamoyl anhydrides}$ (10a) as described by F. J. Brown, et al. in Eur. Pat. Appl. EP 199543 (see Scheme 8).

Scheme 9


15

20

25

30

35



Aniline intermediates (63) are disclosed in U.S. Patent No. 4,355,040 and may be obtained from the corresponding nitro compound precursor by reduction. A variety of reduction procedures may be used such as 5 iron/acetic acid, D. C. Owsley, J. J. Bloomfield, Synthesis, 118, (1977), stannous chloride, F. D. Bellamy, Tet. Lett., 839, (1984) or careful hydrogenation over a metal catalyst such as palladium.


As shown in Scheme 9, aniline intermediates of 10 N-benzylimidazoles may also be prepared from the corresponding carboxylic acid (10) or acid chloride via a Curtius rearrangement of an intermediate acyl azide (60). More modern methods include using diphenylphosphoryl azide as a source of azide, T. Shioiri, 15 K. Ninomiya, S. Yamada, J. Am. Chem. Soc., 94, 6203 (1972), and trapping the intermediate isocyanate (61) produced by the Curtius rearrangement with 2-trimethylsilylethanol and cleaving the resultant carbamate (62) with fluoride to liberate the amine (63), T. L. Capson 20 and C. D. Poulter, Tet. Lett., 25, 3515 (1984). Classical procedures familiar to one skilled in the art may also be employed.

Compounds where R¹ is -SO₂NH₂ may be made as shown in Scheme 10:

25

30

35

Scheme 10

Sulfonamide compounds (65) may be made by reacting an arylsulfonyl chloride (64) with ammonia, or its equivalent. Unsubstituted arylsulfonamides are made by reaction with ammonia in aqueous solution or in an inert organic solvent, F. H. Bergheim and W. Braker, J. Am. Chem. Soc., 66, 1459 (1944), or with dry powdered ammonium carbonate, E. H. Huntress and J. S. Autenrieth, J. Am. Chem. Soc., 63, 3446 (1941); E. H. Huntress and F. H. Carten, J. Am. Chem. Soc., 62, 511 (1940).

The sulfonyl chloride precursor may be prepared by chlorosulfonation with chlorosulfonic acid on the aromatic ring directly, E. H. Huntress and F. H. Carten, ibid.; E. E. Gilbert, op. cit., 84, or by reacting the corresponding aromatic diazonium chloride salt (53) with sulfur dioxide in the presence of a copper catalyst, H. Meerwein, et al., J. Prakt. Chem., [11], 152, 251 (1939), or by reacting the aromatic sulfonic acid (46) with PCl_5 or POCl_3 , C. M. Suter, The Organic Chemistry of Sulfur, John Wiley, 459 (1948).

Linked ester compounds of formula (I) where R¹

0

is -CO₂CH(R²⁴)OCR²¹ can be made by procedures well known in penicillin and cephalosporin chemistry. The

5 purpose is to provide materials which are more lipophilic and which will be useful orally by rapid transit from the gut into the bloodstream, and which will then cleave at a sufficiently rapid rate to provide therapeutically useful concentrations of the active

10 carboxylic acid form. The following review articles and references cited therein discuss this concept and the chemistry involved in preparing such compounds V. J. Stella, et al., Drugs, 29, 455-473 (1985); H. Ferres, Drugs of Today, 19 (9), 499-538 (1983); A. A. Sirkula, Ann. Repts. Med. Chem., 10, 306-315 (1975).

15

Experimental procedures which are applicable to the preparation of chemically stable linked esters are illustrated by equations a-e of Scheme 11.

20

25


30

35


44

Scheme 111066

5 G. Francheschi et al.. J. Antibiotics. 36. (7).
938-941 (1983).

67

15 J. Budavin, U.S. Patent 4,440,942



20

68

B. Daehne et al.. G.B. Patent 1,290,787




25

69

Ferres, Chem. Ind., 435-440 (1980)

30



35


70

SUBSTITUTE SHEET

45

Clayton et al., Antimicrob. Agents Chemotherapy,
5, (6), 670-671 (1974)

5



10

Compounds of Formula I where R¹ is -C(CF₃)₂OH may be prepared as shown in Scheme 12.

15

20


25

30

35

SUBSTITUTE SHEET

Scheme 12




15 Hexafluoroisopropanol compounds (72) may be prepared by treatment of arylsilane (71) with 1-5 equivalents of hexafluoroacetone in a solvent such as methylene chloride at temperatures ranging from about -50° to 25°C for a period of 2-10 hours. The requisite arylsilane (71) can be prepared using methods known to one skilled in the art such as the procedures described
20 in Chapter 10 of Butterworth's "Silicon in Organic Chemistry".

25

30

35

Scheme 13

As shown in Scheme 13, compound (73) in which X= -NHCO and R¹³= -COOH may be easily prepared, for example, by reacting aniline precursor (63) with a phthalic anhydride derivative in an appropriate solvent such as benzene, chloroform, ethyl acetate, etc. Often the carboxylic acid product will precipitate from solution with the reactants remaining behind,

5 M.L. Sherrill, F.L. Schaeffer, E.P. Shoyer, J. Am. Chem. Soc., 50, 474 (1928).

When R¹³=NHSO₂CH₃, NHSO₂CF₃ or tetrazoyl (or a variety of other carboxylic acid equivalents), compound (73) may be obtained by reacting aniline (63) with the requisite acid chloride by either a Schotten-Baumann procedure, or simply stirring in a solvent such as

10 methylene chloride in the presence of a base such as sodium bicarbonate, pyridine, or triethylamine.


15 Likewise, aniline (63) may be coupled with an appropriate carboxylic acid via a variety of amide or peptide bond forming reactions such as DCC coupling, azide coupling, mixed anhydride synthesis, or any other coupling procedure familiar to one skilled in the art.

20 Aniline derivatives (63) will undergo reductive amination with aldehydes and ketones to form secondary amines (74). Thus the aniline is first stirred with the carbonyl compound in the presence of a dehydration catalyst such as molecular sieves or p-toluenesulfonic acid. Afterwards the resultant imine is reduced to the amine with a borohydride reducing agent such as sodium cyanoborohydride or sodium borohydride. Standard

25 catalytic hydrogenation reagents such as hydrogen and palladium/carbon can also be employed.

30 Alternatively, aniline (63) may be monoalkylated by reaction with ethyl formate followed by reduction with, for example, lithium aluminum hydride to produce the N-methyl derivative (74). Anilines (74) may in turn

50
Scheme 14



SUBSTITUTE SHEET

be reacted with carboxylic acid anhydrides and acid chlorides or carboxylic acids by any of the coupling procedures described previously to yield (73) where X= -N(CH₃)CO-.

5 Aniline (63) or (74) or other intermediate anilines where the amino group may be located on another aromatic ring for example, also react with other anhydrides to make amide-carboxylic acid derivatives of formula (75). Thus, for example, maleic anhydride,
10 2,3-naphthalenedicarboxylic acid anhydride, and diphenic anhydride are reacted in a similar fashion to phthalic anhydride with aniline (63) or (74) to yield carboxylic acids (76), (77), and (78), respectively.


15 Phthalimide derivatives of aniline (63) may be made by a variety of methods, preferably by stirring aniline (63) with phthalic anhydride in acetic acid at a temperature between 20°C and reflux, G. Wanag, A. Veinbergs, *Ber.*, 75, 1558 (1942), or by stirring (63) with phthaloyl chloride, a base such as triethylamine, 20 and an inert solvent.

25 Aniline (63) may be converted into its trifluoromethanesulfonamide derivative or its trifluoroacetamido derivative preferably by reacting it with triflic anhydride or trifluoroacetic anhydride and a base such as triethylamine in an inert solvent such as methylene chloride at -78°C followed by warming to room temperature.

30 Compounds of structure (I) where X is a carbon-carbon linkage which are depicted as (80) can be made as shown in Scheme 14.

Scheme 14 (continued)

e)



15 Equation a) illustrates that the biphenyl compounds (80) can be prepared by alkylation of imidazole (1) with the appropriate halomethylbiphenyl compound (79) by the general procedure described in Scheme 1.

20 The requisite halomethylbiphenyl intermediates (79) are prepared by Ullman Coupling of (81) and (82) as described in "Organic Reactions", 2, 6 (1944) to provide intermediates (83), which are in turn halogenated. Halogenation can be accomplished by refluxing (83) in an inert solvent such as carbon tetrachloride for 1-6 hours in the presence of a N-halosuccinimide and an initiator such as azobisisobutyronitrile (equation b).


25 As shown in equation c), derivatives of intermediate (83) in which R¹³ is at the 2' position (83a) can also be prepared by the method described in J. Org. Chem., 41, 1320 (1976), that is Diels-Alder addition of a 1,3-butadiene to a styrene (84) followed by aromatization of intermediate (85).

30 Alternatively, the substituted biphenyl precursors (83; where R¹³ = COOH) and their esters (89) can be prepared as illustrated in equation d), which involves oxazoline compounds as key intermediates, A. I. Meyers and E. D. Mihelich, J. Am. Chem. Soc., 97, 7383 (1975).

Further, as shown in Equation e), nickel-catalyzed cross-coupling of an arylzinc halide with a halobenzonitrile yields a biphenylnitrile which can in turn be hydrolyzed by standard methods to afford acid

5 88.

The substituted biphenyl tetrazoles (83; where



10 precursors ($R^{13}=CN$) by the methods described in Scheme 1, equation c) and Scheme 15, equation c).

15 However, a preferred method for preparing tetrazoles is described in Scheme 15, equations a) and b). Compounds (90) may be prepared by the 1,3-dipolar cycloaddition of trialkyltin or triphenyltin azides to the appropriately substituted nitrile (83) as in equation a). Alkyl is defined as normal alkyl of 1-6 carbon atoms and cyclohexyl. An example of this technique is described by S. Kozima, et al., J. Organometallic Chemistry, 337 (1971). The required trialkyl or triaryltin azides are made from the requisite commercial trialkyl or triaryl tin chloride and sodium azide. The trialkyl or triaryltin group is removed via acidic or basic hydrolysis and the tetrazole can be protected with the trityl group by reaction with trityl chloride and triethylamine to give (91). Bromination as previously described herein with N-bromosuccinimide and dibenzoylperoxide affords compound (92). Alkylation of (1) with the 20 appropriately substituted benzyl halide using conditions previously described followed by deprotection of the trityl group via hydrolysis affords (80; $R^{13} = \text{tetrazole}$). Other protecting groups such as 25 p-nitrobenzyl and 1-ethoxyethyl can be used instead of the trityl group to protect the tetrazole moiety.


30

35

These groups as well as the trityl group can be introduced and removed by procedures described in Greene, Protective Groups in Organic Synthesis, Wiley-Interscience, (1980).



5

Scheme 15



.35

54

Scheme 15 (continued)

25

30

35

SUBSTITUTE SHEET

Compounds of structure 93-95 where X is an
-O-, -S-, or -N- linkage can be prepared as shown




5


in Scheme 16 by alkylation of imidazole (1) with the appropriate benzyl halide (96).

Scheme 16


10



20




30



The halomethyldiphenyl ether (109) employed as an alkylating agent in the present invention is prepared as shown in equation b). An Ullman ether condensation of the phenol (97) and a halobenzoic acid as described in 5 Russian Chemical Reviews, 43, 679 (1974) provides the intermediate acid (101). The conversion of (101) into (109) is accomplished by esterification with diazomethane to afford (105) followed by halogenation employing the procedure used in the preparation of (79).
10 The diphenylsulfide (110) and the diphenylamine (111) can be prepared from the appropriate thiophenol (98) or aniline (99) by this procedure.

The tertiary diphenylamine (112) can be prepared from the secondary aniline (100) by the above procedure.
15 Alternatively (107) can be alkylated by one of the following procedures: 1) direct alkylation of (107) with $R^{26}L$ where L is a leaving group such as a halogen or tosylate employing phase-transfer conditions and ultrasound as described in Tetrahedron Letters, 24, 5907
20 (1983), 2) treatment of (107) with 1-1.5 equivalents of an appropriate aldehyde and 0.5-5.0 equivalents of sodium cyanoborohydride in a solvent such as methanol at 25°C at a pH of 3-6 for 1-24 hours, or 3) reductive amination of (107) employing an appropriate carboxylic acid and sodium borohydride as described in J. Am. Chem. Soc., 96, 7812 (1974). The tertiary amine (108) is then 25 halogenated by the procedure previously described to give (112).

Scheme 17

30

35

Compounds of structure (73) where X is -CO- are prepared as shown in Scheme 17 by alkylation of imidazole (1) with the requisite benzoylbenzyl halides. For example, esters (113) where R¹³ is 2-CO₂CH₃ are prepared by alkylation of imidazole (1) with carbomethoxybenzoyl benzyl halide (114). Ester (113) may be hydrolyzed to the corresponding carboxylic acid (116) by a variety of methods including hydrolysis with a base such as sodium hydroxide or potassium hydroxide in an alcoholic aqueous solvent such as methanol/H₂O at a temperature from 20°C to the reflux temperature of the solvent.


Carboalkoxybenzoylbenzyl halides (114) are prepared by benzylic halogenation of the corresponding toluoylbenzene precursor by a variety of methods previously described herein. For example, methyl 2-(4-methylbenzoyl)benzoate (115) can be refluxed for 2-48 hours with N-bromosuccinimide, benzoyl peroxide and carbon tetrachloride to effect benzylic bromination.

20


25

30

35

Scheme 18

As shown in Scheme 18 the toluoyl ketones (73; where X=CO) may be further transformed into a variety of ketone derivatives including compounds where X is




Reaction of ketone (73a) with a hydroxylamine or an appropriately substituted hydrazine will give the requisite oximes (117) and hydrazone (118). Reaction with alcohols in the presence of an acidic catalyst with removal of water will give ketals (119). Reduction, with lithium aluminum hydride, a metal borohydride, zinc/acetic acid or catalytic hydrogenation will give the corresponding alcohol (120) or fully reduced methylene compound (121). These alcohols may be acylated by a variety of anhydrides or acid halides in the presence of a base with or without solvent to give the corresponding esters (122). The alcohols (120) may be converted into their corresponding ethers (123) by reaction of the metal alkoxide with an alkyl halide, mesylate or tosylate in the appropriate solvent or by treatment with a mineral acid in an alcoholic solvent, or by reaction of the alcohol with diazomethane as described in G. Hilgetag and A. Martini, "Preparative Organic Chemistry", John Wiley, New York, 355-368 (1972).

Compounds of formula (I) where X is $-\text{OCH}_2-$, $-\text{SCH}_2-$, and $-\text{NHCH}_2-$ are prepared as shown in Scheme 19.

30

35

Scheme 19



As illustrated in Scheme 19, equation a, hydrolysis of benzyl ether (124) or methyl ether (125) affords hydroxy compound (126) which can be alkylated with the appropriate benzyl halide to give (127). In
5 the case of the methyl ethers (125), the hydrolysis step can be effected by heating the ether at temperatures of 50°-150°C for 1-10 hours in 20-60% hydrobromic acid, or heating at 50°-90°C in acetonitrile with 1-5 equivalents of trimethylsilyl iodide for 10-50 hours followed by
10 treatment with water. Hydrolysis can also be carried out by treatment with 1-2 equivalents of boron tribromide in methylene chloride at 10°-30°C for 1-10 hours followed by treatment with water, or by treatment with an acid such as aluminum chloride and 3-30
15 equivalents of a sulfur-containing compound such as thiophenol, ethanedithiol, or dimethyl disulfide in methylene chloride at 0-30°C for 1-20 hours followed by treatment with water. For compound (124), hydrolysis can be accomplished by refluxing in trifluoroacetic acid
20 for 0.2-1 hours or by catalytic hydrogenolysis in the presence of a suitable catalyst such as 10% palladium on carbon. Deprotonation of (126) with a base, such as sodium methoxide, sodium hydride or the like in a solvent such as dimethylformamide or dimethylsulfoxide
25 at room temperature followed by alkylation with an appropriate benzyl halide at 25°C for 2-20 hours affords ethers of formula (127), as shown in equation a.

The sulfide (129) can be prepared from the thiophenol (45) by the procedure described above to
30 prepare the ether (127) from the phenol (126). The thiophenol (45) can be prepared for example by treatment of the benzylsulfide (128) with sodium in liquid ammonia.

The amine (130) can be prepared as shown in
35 equation c, from the aniline (63), itself available from


reduction of the corresponding p-nitro compound (3a) which has previously been described. The reductive amination can be carried out by the same procedure as described in Scheme 13 for the preparation of compound (74).

5

Compounds of Formula (I) where the X linkage is -CH=CH-, -CH₂CH₂-, and  are prepared as shown in Scheme 20.

10

Scheme 20



35

The *cis* or *trans* stilbene (132) can be obtained by employing a Wittig reaction between the aldehyde (57) and the phosphorane (131).

5 The stilbene (132) can readily be converted to the saturated derivative (133) for example by catalytic hydrogenation employing a heterogeneous catalyst such as palladium/carbon or platinum/carbon or alternatively with a homogeneous catalyst such as tristriphenylphosphine rhodium chloride. The reduction is performed in a
10 solvent such as benzene, tetrahydrofuran or ethanol at 25°C under 1-3 atmospheres of hydrogen for 1-24 hours.


15 The cyclopropane (134) can be prepared by treating the stilbene (132) with the Simmons-Smith reagent as described in J. Am. Chem. Soc., 81, 4256 (1959), or by treating (132) with methylene diiodide and copper powder as described in J. Am. Chem. Soc., 101, 2139 (1979), or by treatment with the iron-containing methylene-transfer reagent described in J. Am. Chem. Soc., 101, 6473 (1979).

20 The preparation of compounds of formula (I) where X is -CF₂CH₂-, -CF=CH-, -CH=CF-, -CF=CF- and -CF₂CF₂- are depicted in Scheme 21.

25

30

35

Scheme 21


Vinylene fluorides (137) and (140) can be prepared by reaction of SF₄ or Et₂NSF₃ (DAST) with the appropriate ketone (135) or (138) in which Ar bears a methyl group convertible to a benzylic halide suitable for attachment to an imidazole nitrogen, and Ar' bears a cyano, nitro, ester, or other suitable group which can be subsequently converted to CO₂H, NHSO₂CF₃, etc. The initially formed difluoroethylene (136) and (139) can be formed in a non-polar solvent such as methylene chloride and subsequently converted to the vinylene fluoride by means of alumina, or converted directly into the unsaturated fluoride by running the reaction in a polar solvent such as tetrahydrofuran, diglyme or N-methylpyrrolidone in the presence of mineral acid.

[Equations a and b]. Experimental details of such procedures are found in D.R. Strobach and G.A. Boswell, J. Org. Chem., 36, 818 (1971); G.A. Boswell, U.S. Patents 3,413,321 (1968) and 4,212,515 (1980).

As shown in equation c) an appropriate benzoin (141) may be similarly converted to the corresponding 1,2-difluorostilbene (143). Likewise as shown in equation d) an appropriate benzil (144) can be converted to a tetrafluorodiarylethylene (145) using DAST or SF₄. Experimental details are described in M.E. Christy, et al., J. Med. Chem., 20, (3), 421-430, (1977).

$$\begin{array}{c} \text{R}^{23} \\ | \\ \text{Compounds of formula 1 where } X = -\text{CON}-, -\text{CH}_2\text{O}-, \\ -\text{CH}_2\text{S}-, -\text{CH}_2\text{NH}-, \text{ can be made as shown in Scheme 22.} \end{array}$$

Scheme 22




SUBSTITUTE SHEET

As previously described, acid (10) can be made by alkylating the appropriate imidazole with methyl 4-chloromethylbenzoate in the presence of a base such as potassium carbonate in a polar solvent such as 5 dimethylformamide followed by hydrolysis of the resulting ester. Compound (10) can be converted to (148) by reaction with the requisite amine (146) (R^{13} may need to be protected and subsequently deprotected) and dicyclohexyl carbodiimide (DCC) in methylene 10 chloride [J. R. Beek, et al., J. Am. Chem. Soc., **90**, 4706 (1968)] or by reaction with tosyl chloride in pyridine [J. H. Brewster and C. J. Ciotti, Jr., J. Am. Chem. Soc., **77**, 6214 (1955)]. Yet another process involves conversion of carboxylic acid (10) to its acid chloride 15 with, for example, thionyl chloride followed by reaction with the amine in aqueous base (Schotten-Baumann conditions) or in an organic solvent in the presence of an acid scavenger such as $NaHCO_3$, pyridine or triethylamine, or by other procedures known to form an 20 amide bond between an aromatic acid and an amine.

The compounds where $X = -CH_2O-$, $-CH_2S-$, and $-CH_2NH_2-$ can be made as shown in pathway b. The ester (149) is reduced with a reducing agent such as lithium aluminum hydride in an inert solvent to form the alcohol (150) which can then be reacted with tosyl chloride in 25 pyridine to form tosylate (151), which is in turn reacted in the presence of base with a corresponding phenol (152) thiophenol (153), or aniline (146; where $R^{23} = H$) to form compounds (154), (155) or (156). Again 30 this may require that R^{13} be protected with a suitable protecting group, however modifications necessary because of specific functional groups are understood to be incorporated by one skilled in the art of organic synthesis.

Alternatively, the alcohol (150) can be converted to the corresponding halide with SOCl_2 , $(\text{COCl})_2$, etc, and the resulting halide can then be reacted with a phenol, thiophenol or aniline in the presence of base to form the desired compound, where X is $-\text{CH}_2\text{O}-$, $-\text{CH}_2\text{S}-$, $-\text{CH}_2\text{NH}-$ respectively.

Scheme 23




SUBSTITUTE SHEET

SUBSTITUTE SHEET

Compounds of Formula (I) where X= $-SO_2NR^{23-}$ and $-NR^{23}SO_2-$ may be prepared as shown in Scheme 23. As shown in equation a, sulfonylchloride derivative (157) can be reacted with aniline derivative (158) in a solvent in the presence of an acid scavenger such as sodium bicarbonate, triethylamine or pyridine or under Schotten-Baumann like conditions to give (159). Sulfonylchloride derivative (157) can be obtained by sulfonation of the corresponding benzyl derivative as described earlier, followed by reaction with PCl_5 or $POCl_3$. Likewise, aniline (74) may be reacted in the same manner as described above with sulfonylchloride derivative (160) to give (161).

Scheme 24 shows the preparation of furan analogs of the biphenyl compounds (80). Thus, α -ketoester (162), W. Wierenga and H. I. Skulnick, J. Org. Chem., 44, 310 (1979), or the corresponding nitrile (E=CN) can be easily alkylated via standard procedures already mentioned by an alkyl bromide derivative to give (163). The alkene moiety of (163) can be subsequently cleaved by oxidation, for example, with osmium tetroxide, Fieser and Fieser, V.1, p. 812 (Lemieux-Johnson oxidation) to yield dicarbonyl-containing compound (164). Cyclization in mineral acids, acidic ion-exchange resin, $POCl_3$ /pyridine, or trifluoroacetic anhydride with a catalytic amount of trifluoroacetic acid yields furan (165; Z=O). Reaction of (164) with P_4S_10 , for example, will yield the corresponding thiophene (165; Z=S). Reaction of (164) with an amine in refluxing benzene, with azeotropic removal of water or by using molecular sieves to absorb the water will yield the corresponding pyrrole (165; Z=NR¹¹). Compounds (166) may be prepared from (165) by standard procedures already described.



SUBSTITUTE SHEET

Compounds wherein a methylene group is inserted between the terminal aromatic ring and the acidic functionality may be prepared as shown in Scheme 25, equation a). Thus reduction of ester (167) with, for example, lithium aluminum hydride, gives alcohol (168). Conversion of (168) to the chloride (169) via thionyl chloride followed by reaction with cyanide anion as previously described yields nitrile (170). Compound (170) may be hydrolyzed to carboxylic acid (171) by methods already described or reacted with a hydrazoic acid equivalent to produce tetrazole (172).

Compounds wherein R¹³ is a trifluoromethylsulfonyl hydrazide acidic functional group were prepared by the procedure described in equation b). That is, conversion of ester (167) to the hydrazide (173) by standard hydrazinolysis followed by reaction with triflic anhydride affords hydrazides (174).

20





25

30

35

73

Scheme 25



SUBSTITUTE SHEET

The syntheses of compounds wherein R¹³ is substituted and unsubstituted 1,2,3-triazoles are described in Scheme 26. Thus reduction of ester (175) with a reducing agent such as lithium aluminum hydride or diisobutylaluminum hydride gives alcohol (176).
5 Oxidation with MnO₂ or pyridinium chlorochromate converts (176) into aldehyde (177). Nitroethylene derivative (178) is prepared by condensation of aldehyde (177) with nitromethane in the presence of a catalyst.
10 R. M. Letcher and M. P. Sammes, J. Chem. Ed., 62, 262 (1985). Reaction of (178) with sodium azide produces the 1,2,3-triazole (179), (N. S. Zefirov, et al., J. Chem. Soc. Chem. Comm., 1001 (1971)) which may be transformed via procedures already described into product (180).

15 Aldehyde (177) can also be converted into substituted 1,2,3-triazoles (183) via the sulfone (181), G. Beck, D. Gunther Chem. Ber., 106, 2758 (1973), followed by reaction with sodium azide to give the 20 1,2,3-triazole (182). Subsequent standard manipulations lead to 1,2,3-triazoles (183) where E=CN and CO₂R¹¹. The nitrotriazole (183; E=NO₂) may be synthesized from the unprotected triazole (179; P=H) via nitration, R. Huttel, et al., Chem. Ber., 88, 1586 (1955), C. L. 25 Habraken and P. Cohen-Fernandes J. Chem. Soc., 37 (1972), or from bromonitroethylene derivative (184), G. Kh. Khisamutdinov, et al., Zh. Org. Khim., 11, 2445 (1975), by reaction with sodium azide.

30 A variety of protecting groups may be used in the manipulation of the above triazoles, amongst which is the trityl group. This group may be easily attached by reaction of the triazole with triphenylmethyl bromide or chloride in an inert solvent such as methylene chloride in the presence of an acid scavenger such as triethyl 35 amine. The trityl group may be later removed by

stirring or refluxing in an acidic medium such as trifluoroacetic acid/water, HCl in methylene chloride, or acetic acid/water. The trityl group may also be hydrogenolyzed using a noble metal catalyst such as 5 palladium and hydrogen.

10

15

20


25

30

35

76

Scheme 26



76

SUBSTITUTE SHEET


The synthesis of trifluoromethyl-1,2,4-triazole (190) is depicted in Scheme 27. Acid chloride (186) is converted to amide (187) using standard procedures familiar to one skilled in the art. A preferred protecting group is the 2-propionitrile group ($P=CH_2CH_2CN$). Thus (187; $P=CH_2CH_2CN$) can be synthesized from (186) and β -aminopropionitrile under Schotten-Baumann like conditions, using aqueous base in an organic solvent to help solubilize (186) and (187). Amide (187) is converted to amidrazone (188) by reaction with PCl_5 or phosgene to make an iminoyl chloride which then in turn is reacted with excess hydrazine. Amidrazone (188) is cyclized to the trifluoromethyl-1,2,4-triazole (189) with trifluoroacetic anhydride and then converted to (190) via bromination, alkylation and deprotection as previously described.

20

25

30

35



30

35

Pertinent R⁶ groups may be variously introduced by many procedures including those described in Scheme 28 which describes imidazole construction.

The R⁶ groups so introduced may stand unchanged or 5 may be further elaborated if appropriately functionalized, according to methods familiar to those skilled in the art such as are illustrated in Scheme 28.

10




15

20

25

30

35



30

35

The 2-alkenylimidazoles (201) can be prepared by bromination of the 2-alkylimidazoles (199) followed by elimination of hydrogen bromide. The bromination is preferably accomplished by UV-irradiation for 1-4 hours of imidazole (199) and N-bromosuccinimide, in an inert solvent, such as carbon tetrachloride at 25°C.

5 Treatment of the intermediate bromide (200) with a base, such as DBU, triethylamine, or potassium t-butoxide, affords the trans 2-alkenylimidazoles (201). Cis 10 alkenyl derivatives (203) are prepared from the trans alkenyl compounds by treatment with osmium tetroxide and sodium periodate to afford aldehydes (202) followed by Wittig reaction.


15

20

25

30

35



R = alkyl, cycloalkyl

30

35

Alternatively, R⁶ groups may be introduced by metallation of a protected imidazole or protected 2-methylimidazole followed by addition of an appropriate electrophile as illustrated in Scheme 30, equations a)

5 and b). The products (alcohols, esters, halides, aldehydes, alkyls) are suitable for further elaboration by methods familiar to those skilled in the art.

Metallation of imidazoles is described in K.L. Kirk, J. Org. Chem., **43**, 4381 (1978); R.J. Sundberg, J. Het. Chem., **10**, 517 (1977); J.V. Hay et al., J. Org. Chem., **38**, 4379 (1973); B. Iddon, Heterocycles, **23**, 417 (1985).


15 Condensation of 2-methylimidazole and appropriate electrophiles (equation b) with catalytic acid or base as described in A.R. Katritzky (Ed.), "Comprehensive Heterocyclic Chemistry", Vol. 5, p. 431, Pergamon Press, N.Y., 1984 affords products wherein R₆ is alkenyl which are suitable for further elaboration.

20

25

30

35




25

30

35

Various 2-substituted imidazoles can be prepared by reaction of a protected 2-trimethylsilylimidazole with a suitable electrophile by the method described by F.H. Pinkerton and S.F. Thames, J. Het. Chem., **9**, 67 (1972), which can be further elaborated as desired. Alternatively, R⁶ may also be introduced by nickel catalyzed cross-coupling of Grignard reagents with 2-(methylthio)imidazoles (Scheme 31) as described by E. Wenkert and T.W. Ferreira, J. Chem. Soc., Chem. Commun., 840, (1982); E. Wenkert et al., J. Chem. Soc., Chem. Commun., 637, (1979); and H. Sugimura and H. Takei, Bull. Chem. Soc. Japan, **58**, 664 (1985). The 2-(methylthio)imidazoles can be produced by the procedure described in German Patent No. 2,618,370 and the references cited therein.

Scheme 31

As shown in Schemes 32-36, elaboration of R⁸ can be accomplished by some of the procedures described in Schemes 3 and 28, by chain extension reactions familiar to those skilled in the art, or by degradation reactions such as conversion of an ester to an acid or an alkene to an aldehyde.


Specifically, the hydroxymethyl group can be activated for the displacement reaction by reacting with thionyl chloride, PCl₅ or with carbon tetrachloride/triphenylphosphine to form a corresponding chloro derivative. By a similar reaction bromo and iodo derivatives can be obtained. The hydroxymethyl group can also be activated by forming the corresponding p-toluenesulfonate, methanesulfonate and trifluoromethane sulfonate derivatives.

20

25

30

35

Schem 32

30

35


As shown in Scheme 32, the hydroxyl group can be converted to thiolacetic acid derivative (215), J. Y. Gauthier, Tet. Lett., 15 (1986), and to thiol derivative (216) by subsequent hydrolysis.

The hydroxymethyl group on compound (17) can be readily oxidized to an aldehyde group by means of manganese dioxide or ceric ammonium nitrate. The aldehyde group will undergo chain extension reactions such as the Wittig and Wittig-Horner reactions and enter into typical carbon-carbon bond forming reactions with Grignard and lithium reagents as well as with compounds bearing activated methylene groups. Alternatively, the hydroxymethyl group can be oxidized directly to an acid functionality which can in turn be converted to ester and amide derivatives. The esters and amides can be prepared directly from the aldehydes by manganese dioxide oxidation in the presence of sodium cyanide and an alcohol or amine, J. Am. Chem. Soc., 90, 5616 (1968) and J. Chem. Soc. (C), 2355 (1971).

As shown in Scheme 33, the chlorine on compound (25) can be displaced by the anion of dialkyl malonate to give the corresponding malonate derivative (217). The saponification of (217) with NaOH (or KOH) gives the corresponding diacid which can be decarboxylated to give the corresponding propionic acid derivative (218) by heating to 120°C. Alternatively, (218) can be directly obtained by refluxing (217) with a mineral acid such as HCl or sulfuric acid. The free acid (218) can be esterified by heating in a medium of the various alcohols and a catalytic amount of mineral acids such as HCl or sulfuric acid to give the corresponding esters (219). Alternatively the esters can be obtained by reacting the free acid (218) and the corresponding alcohols in the presence of coupling reagents such as DDQ or EEDQ. A similar reaction with various mono-

substituted and disubstituted amines produces the corresponding amides (220). A similar reaction with various mercaptans produces the corresponding thioesters.

5

Scheme 33

25

30

35

As shown in Scheme 34, the chloro group on (22) can be displaced by the sodium salt or potassium salt of the alkyl, aryl or arylalkyl mercaptans to give the corresponding sulfide derivatives (221). The amine derivative (222) can be obtained by treating (25) with ammonia or with the corresponding mono-substituted amines. Alternatively, the chloro group may be displaced by sodium azide to give an azide intermediate which upon reduction with H₂ over a noble metal catalyst or with a reducing agent such as chromous chloride (W. K. Warburton, J. Chem. Soc., 2651 (1961)) yields (222) where R¹⁰ and R¹¹ are hydrogen. This amine can be subsequently alkylated with alkyl halides, or reductively alkylated with aldehydes and ketones to give alkyl derivatives of (222). The amines (222) are converted to the corresponding carbamates (224), sulfonamides (225), amides (226) or ureas (227) by standard procedures illustrated in Scheme 34 and familiar to one skilled in the art.


20

25


30

35

Scheme 34




Scheme 34 (Cont'd)




15 The reaction between the thiopyridyl ester (229)
and a suitable Grignard reagent produces the ketones
(230).

Scheme 35



30 As shown in Scheme 36 when the imidazole 4- and/or
5-position contains an aldehyde (231) then reaction with
organometallic reagents such as Grignard or
alkyl/aryllithium reagents will yield alcohols (232)
which in turn may be transformed into a variety of other
functionality familiar to one skilled in the art.

35


Scheme 36

As shown in Scheme 37, ester 234 may be obtained
 25 by direct oxidation of aldehyde 233 with NaCN, MnO₂ in
 methanol (Corey, E. J., et al. J. Am. Chem. Soc. (1968)
90, 5616). Oxidation of 233 with NaCN, MnO₂, and an
 amine in 2-propanol leads to the corresponding amide 235
 (Gillman, N. W. Chem. Comm. (1971) 733).

30

35

Scheme 37



25 Saponification of ester 234 will lead to
carboxylic acid 236.

Aldehyde 233, in turn, may be made from the corresponding alcohol 17 by a variety of methods familiar to one skilled in the art, including pyridium chlorochromate (PCC), Swern and ceric ammonium nitrate (CAN) oxidations.

Likewise, the unalkylated hydroxymethylimidazole derivative 1 ($\text{R}^8=\text{CH}_2\text{OH}$) may undergo the transformations to the aldehyde, ester, carboxylic acid and carboxamide by the reactions mentioned above for the alkylated case.

Compounds 238 (where Ar = p-biphenylyl, p-phenoxyphenyl, or a heteroaryl group as described in the scope under the definition of R⁷) can be prepared by the coupling of an arylmetal derivative (ArM, where M=ZnBr, Me₃Sn, B(OH)₂, etc.) with a haloimidazole 237 in the presence of a transition metal catalyst such as palladium, nickel, platinum, zirconium, etc. (Scheme 38a). Alternatively an imidazole metal derivative 239 can be coupled to an arylhalide to prepare 238 (Scheme 38b).

The arylmethyl derivatives 240 can be prepared employing the transition metal catalysed coupling of 237 and an arylmethyelmet (ArCH₂M', where M'=ZnBr, etc.), as shown in Scheme 38c.

Compounds 241 may be prepared, as described in Scheme 38d, by the coupling of an alkenyl- or alkynylmetal derivative (AM) or the corresponding alkene or alkyne (AH) with 237.

Likewise, the unalkylated imidazoles (1, where R⁷=Br or I) may undergo the coupling reactions described in Scheme 38a-d [For references to transition metal catalysed coupling reactions, see: Richard C. Heck, Palladium Reagents in Organic Synthesis, Academic Press, New York, Chapters 6, 7, and 8; and references cited therein.]

The compounds of formula I where R⁷ is an alkynyl group, a substituted alkynyl group, or a substituted alkenyl group and the carbon-carbon double or triple bond is not adjacent to the imidazole ring (e.g., R⁷=(CH₂)₄CH=CH(CH₂)_vAr, where v≠0) can be prepared by a variety of chain elongation methods and chain coupling reactions known to one skilled in the art including those described in Schemes 3, 28, 29, 33, 35, 36, and 38.

WO 91/00277

PCT/US90/03683

The compounds of formula I where R⁷ is a substituted alkyl group (R⁷=(CH₂)_wAr, where w=2-10) can be prepared by reduction of the corresponding alkenes (241) by catalytic hydrogenation.

5

10

15


20

25

30

35

Scheme 38




SUBSTITUTE SHEET

Scheme 38 (cont.)


5

d)

237



10



15

A = VINYL
 $\text{CH}=\text{CH}(\text{CH}_2)_x\text{Ar}$
 $\text{C}\equiv\text{C}(\text{CH}_2)_y\text{CH}_3$
 $\text{C}\equiv\text{C}(\text{CH}_2)_z\text{Ph}'$
 $\text{C}\equiv\text{C}(\text{CH}_2)_x\text{Ar}'$

241

20

$x = 0-8$
 $y = 0-7$
 $z = 0-4$

25

30

35

Compounds of formula I where R⁷ = vinyl or arylalkenyl and R⁸ = CH₂OH, aldehyde, or COOH can be prepared as shown in Scheme 39.

5 2-Alkylimidazole-4,5-dicarboxylic acids (242), prepared by the method of R.G. Fargher and F.L. Pyman (J. Chem. Soc., (1919) 115, 217), can be converted into their corresponding diesters (243) by simply refluxing in an alcohol solvent in the presence of an acid such as HCl, or by many other methods familiar to one skilled in
10 the art.

Diester (243) can then be converted into its metallic salt by reaction with sodium methoxide, sodium ethoxide, sodium hydride, potassium hydride or any other base in an appropriate solvent such as DMF. The
15 resultant salt is then alkylated with the appropriately substituted benzyl derivative (2) to yield benzylimidazole (244). The above alkylation sequence may be also performed by heating or refluxing the benzyl halide (tosylate or mesylate) (2) with imidazole (243)
20 in a solvent such as DMF in the presence of an acid scavenger such as potassium or sodium carbonate.

Diester (244) can be reduced with lithium aluminum hydride in an inert solvent such as THF to the corresponding dialcohol (245). Selective oxidation of
25 dialcohol (245) with manganese dioxide in an inert solvent such as THF yields primarily aldehyde (247) with a minor product dialdehyde (246). Separation of (247) from (246) either by crystallization or chromatographically, followed by Wittig reaction of
30 (247) with methylenetriphenylphosphorane or the appropriately substituted arylalkyldenetriphenyl-phosphorane in an inert solvent such as THF yields the 4-alkenyl-5-hydroxymethylimidazole (248). Further oxidation of (248) with the Dess-Martin periodinane (J. Org. Chem., (1983) 48, 4155), with manganese dioxide;

with pyridinium chlorochromate, with barium manganate or
with other oxidants familiar to one skilled in the art,
in an inert solvent such as THF or methylene chloride
followed by deprotection of either R¹, R², or R³ if
necessary yields the 4-alkenylimidazole-5-carboxaldehyde
(249).

Oxidation of (249) with, for example, manganese
dioxide/cyanide ion (Corey, E.J., et al. J. Am. Chem. Soc., (1968) 90, 5616) or with potassium permanganate
(Sam, D.J. et al. J. Am. Chem. Soc., (1972) 94, 4024)
yields 4-alkenylimidazole-5-carboxylic acid (250).

15


20

25

30

35

Scheme 39



where T=H, y=H, $(\text{CH}_2)_x$ -Aryl or T and y taken together form a cyclic ring of 3-8 carbons and the regiochemistry about the double bond in 248, 249 and 250 can be Z or E.


Imidazoles represented by structure (251) where X is Cl, Br, or I and E is an electron withdrawing group such as an ester, ketone, nitro, alkylsulfonyl, arylsulfonyl, etc., can undergo the nucleophilic aromatic substitution reaction (H. Schubert, H. Simon, A. Jumar, Z. Chem. (1968) 62-63) where the leaving group X is substituted by a nucleophile such as sulfur, carbon, or nitrogen to yield adducts (252) (Scheme 40). The reaction can be done in hydroxylic solvent such as methanol or non-hydroxylic solvent such as DMSO at room temperature to the reflux temperature of the solvent. The nucleophile sometimes must be converted into its anion to make it more nucleophilic. For example, thiophenol can be refluxed in methanol in the presence of sodium methoxide and the haloimidazole (251). Other nucleophiles include other alkyl and arylthiols, heteroarylthiols, thiolacetic acid, alkyl and arylsulfonamides, heteroarylsulfonamides, diacylamines, alkyl and arylamines, heteroarylamines, etc., familiar to one skilled in the art.

If a sulfur nucleophile is used, the resultant sulfides can be oxidized to the corresponding sulfoxides and sulfones by methods familiar to one skilled in the art.

25

30

35



The compounds of this invention and their preparation can be understood further by the following examples, which do not constitute a limitation of the invention. In these examples, unless otherwise indicated, all temperatures are in degrees centigrade and parts and percentages are by weight.

20


25

30

35

Example 1


5



10 PART A: Preparation of 2-n-Propyl-4,5-dicarbomethoxyimidazole.

2-n-Propylimidazole-4,5-dicarboxylic acid
15 [prepared by the method of R.G. Fargher and F.L. Pyman
(J. Chem. Soc., (1919) 115, 217), mp 257 (dec.) °C]
(17.14 g, 86.6 mmol, 1 eq), methanol (400 mL) and
acetyl chloride (38.1 mL, 534 mmol, 6 eq) were
cautiously mixed (acetyl chloride addition to methanol
20 is very exothermic) and refluxed overnight. The
solvent was removed in vacuo and water (100 mL) and 10
N NaOH were added until pH=7. The aqueous mixture was
extracted with ethyl acetate (3X), the organic layers
combined, dried ($MgSO_4$) and the solvent removed in
vacuo to yield 12.00 g of a white solid.
25 Recrystallization from hexane/ethyl acetate yielded
11.41 g of a white solid (58%); mp: 162.0-164.5°C.
NMR ($CDCl_3$) δ 3.95 (s, 6H); 2.78 (t, 2H); 1.83 (t of t,
2H, J=7, 7Hz); 0.97 (t, 3H, J=7Hz); IR (neat) 1735 cm⁻¹.
30 Anal. calcd. for $C_{10}H_{14}N_2O_4 \cdot (H_2O)_{0.25}$: C, 52.06; H,
6.28; N, 12.14. Found: C, 52.06; H, 6.17; N, 12.49.

5



10


Part B: Preparation of 4-Methyl-2'-(N-triphenylmethyl)-
15 (1H-tetrazol-5-yl)biphenyl

4'-Methylbiphenyl-2-nitrile (preparation described in European patent application 0253310, published on 20.01.88) (10.00 g, 51.7 mmol, 1 eq), tri-n-butyltin chloride (14.0 mL, 51.7 mmol, 1 eq), sodium azide (3.4 g, 51.7 mmol, 1 eq), and xylene (50 mL) were mixed and refluxed for 64 h after which the reaction mixture was cooled to room temperature. 10.0 N NaOH (6.10 mL, .061 mmol, 1.2 eq) and trityl chloride (14.99 g, 53.8 mmol, 1.04 eq) were then added and the mixture stirred for 24 h after which water (39 mL) and heptane (100 mL) were added. The resultant slurry was stirred at 0°C for 1.5 h. The resultant solids thus obtained were filtered, washed with water (2X 55 mL) washed once with 3:2 heptane/toluene (55 mL) and dried overnight under high vacuum to yield 19.97g of a light yellow powder: mp 148.0-155.0°C (dec.). These solids were slurried in ethyl acetate (75 mL) and filtered to yield 15.0g of a light yellow powder: mp 164.0-165.5°C

(dec.). NMR (CDCl_3) δ 7.91 (d, 1H, $J=9\text{Hz}$); 7.53-7.18 (m, 13H); 7.02-6.84 (m, 9H); 2.25 (s, 3H).

5

10



PART C: Preparation of 4-Bromomethyl-2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl.

15 a representative procedure.

20


4-Methyl-2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl (52.07 g, 109 mmol, 1 eq), N-bromosuccinimide (19.4 g, 109 mmol, 1 eq), benzoyl peroxide (1.0 g) and carbon tetrachloride (300 mL) were mixed and refluxed for 2.5 h. The reaction was cooled to room temperature and the succinimide filtered. The filtrate was concentrated and the residue triturated with ether to yield a first crop of 36.0 g: mp 129.5-133.0°C (dec.). NMR (CDCl_3) δ 4.37 (CH_2Br). This material was suitable for further transformation.

25

30

35

5



10

15

PART D: Preparation of 4,5-dicarbomethoxy-2-n-propyl-1-[(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl))biphenyl-4-yl)methyl]imidazole.

20

Sodium hydride (1.06 g, 44.2 mmol, 1 eq) was added to a solution of 4,5-dicarbomethoxy-2-n-propylimidazole (10.00 g, 44.2 mmol, 1 eq) in DMF at room temperature. Foaming and gas evolution occurred. The temperature was increased to 60°C for 15 minutes to dissolve all of the sodium hydride. Gas evolution ceased and the mixture was cooled to room temperature. To this mixture was added a DMF solution of 4-bromomethyl-2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl))biphenyl (24.64 g, 44.2 mmol, 1 eq). After 24 h, the solvent was removed in vacuo, and the residue was flash chromatographed in 75:25 hexane/ethyl acetate to 100% ethyl acetate over silica gel to yield 15.78 g (51%) of a white glass which was suitable for further transformation. Recrystallization from ethanol yielded


25

30

35

an analytical sample (white crystals); mp: 124.0-125.5°C. NMR (CDCl_3) δ 7.91 (d of d, 1H, $J=3,9$ Hz); 7.59-7.20 (m, 12H); 7.09 (d, 2H, $J=9$ Hz); 6.94 (m, 6H); 6.76 (d, 2H, $J=9$ Hz); 5.30 (s, 2H); 3.89 (s, 3H); 2.50 (t, 2H, $J=7$ Hz); 1.67 (t of t, 2H, $J=7,7$ Hz); 0.85 (t, 3H, $J=7$ Hz). IR (neat) 1718 cm^{-1} . Anal. calcd. for $\text{C}_{43}\text{H}_{38}\text{N}_6\text{O}_4$: C, 73.49; H, 5.45; N, 11.96. Found: C, 73.23; H, 5.48; N, 12.22.

10



15

20 PART E: Preparation of 4,5-dihydroxymethyl-2-n-propyl-1-[(2'-(N-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole.

25

4,5-Dicarbomethoxy-2-n-propyl-1-[(2'-(N-triphenylmethyl-1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole (9.88 g, 14.1 mmol, 1 eq) was dissolved in a minimum of THF and to this solution, lithium aluminum hydride (1.0 M in THF) (15.48 mL, 15.48 mmol, 1.1 eq) was slowly added dropwise. The mixture was allowed to stir at room temperature overnight after which it was quenched by the Steinhardt procedure (Fieser & Fieser V.1, p.584) as follows: to the reaction mixture water (0.66 mL) was first carefully added followed by 15% NaOH (0.66 mL) followed by water (1.97 mL). After stirring for 72 h, a very

30

35

fine suspension of particulate had formed which was slowly filtered through CeliteTM. The filtrate was dried ($MgSO_4$) and the solvent removed in vacuo to yield 8.83 g of a yellow glass which could not be recrystallized. This intermediate was suitable for further transformation. NMR ($DMSO-d_6$) δ 7.82 (d, 1H, J=9Hz); 7.68-7.28 (m, 12H); 7.05 (d, 2H, J=9Hz); 6.87 (d, 6H, J=9Hz); 5.16 (s, 2H); 4.94 (t, 1H, J=7Hz); 4.66 (t, 1H, J=7Hz); 4.37 (d, 2H, J=7Hz); 4.32 (d, 2H, J=7Hz); 2.34 (t, 2H, J=7Hz); 1.52 (t of q, 2H, J=7, 7Hz); 0.77 (t, 3H, J=7Hz). IR (neat) 3300 br; 3061; 1027; 1006; 909; 732; 699 cm^{-1} . Anal. calcd. for $C_{41}H_{38}N_6O_2 \cdot H_2O$: C, 74.07; H, 6.06; N, 12.64. Found: C, 74.06; H, 5.95; N, 11.86.

15

20

25

30


35

PART F: Preparation of 5-hydroxymethyl-2-n-propyl-1-[
[(2'-(N-triphenylmethyl-(1H-tetrazol-5-y1))biphenyl-4-y1)methyl]imidazole-
4-carboxaldehyde and 2-n-propyl-1-[(2'-(N-triphenylmethyl-(1H-tetrazol-5-y1))biphenyl-4-y1)methyl]imidazole-4,5-dicarboxaldehyde.

4,5-Dihydroxymethyl-2-n-propyl-1-[(2'-(N-triphenylmethyl(1H-tetrazol-5-y1))biphenyl-4-y1)methyl]imidazole (8.56 g, 13.2 mmol, 1 eq) was dissolved in a minimum of THF and added to a slurry of manganese dioxide (11.14 g, 128.1 mmol, 9.7 eq) in THF (100 mL) at room temperature. After 24 h, the contents were filtered through Celite™, the cake washed with THF, and the solvent of the filtrate removed in vacuo. The residue was flash chromatographed in 1:1 hexane/ethyl acetate to 100% ethyl acetate over silica gel to yield the dialdehyde which eluted first; 1.25 g (15%) of a tan glass. NMR (DMSO-d₆) δ 10.27 (s, 1H); 10.17 (s, 1H); 7.81 (d, 1H, J=7Hz); 7.68 (m, 2H); 7.50-7.23 (m, 10H); 7.09 (d, 2H, J=9Hz); 6.96 (d, 2H, J=9Hz); 6.86 (m, 6H); 5.59 (s, 2H); 2.52 (t, 2H, J=7Hz); 1.58 (t of q, 2H, J=7,7Hz); 0.77 (t, 3H, J=7Hz). IR (neat) 1697; 1672 cm⁻¹. Anal. calcd. for C₄₁H₃₄N₆O₂: C, 76.62; H, 5.33; N, 13.07. Found: C, 76.46; H, 5.54; N, 12.94.

Continued elution yielded the 4-hydroxymethylimidazole-5-carboxaldehyde product as a light yellow solid: mp 164.5-166.0°C. NMR (DMSO-d₆) δ 9.86 (s, 1H); 7.80 (d, 1H, J=9Hz); 7.63 (t, 1H, J=9Hz); 7.53 (t, 1H, J=7Hz); 7.50-7.25 (m, 10H); 7.07 (d, 2H, J=9Hz); 6.97-6.80 (m, 8H); 5.47 (t, 1H, J=7Hz); 5.29 (s, 2H); 4.63 (d, 2H, J=7Hz); 2.37 (t, 2H, J=7Hz); 1.49 (t of q, 2H, J=7,7Hz); 0.73 (t, 3H, J=7Hz). IR (Nujol) 1688 cm⁻¹. Anal. calcd. for C₄₁H₃₆N₆O₂•(H₂O)_{0.1}: C, 76.16;

H, 5.64; N, 12.84. Found: C, 76.02; H, 5.36; N, 12.84.




PART G: Preparation of 5-hydroxymethyl-2-n-propyl-1-[(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-vinyl-imidazole.

20 n-BuLi (2.5 M in THF) (1.70 mL, 4.3 mmol, 2.1 eq) was added dropwise to a suspension of methyltriphenylphosphonium bromide (1.53 g, 4.3 mmol, 2.1 eq) in THF (50mL) at 0°C under N₂.

The suspension became a dark yellow solution. Afterwards, a solution of 5-hydroxymethyl-2-n-propyl-1-[(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-4-carboxaldehyde (1.31 g, 2.0 mmol, 1.0 eq) in THF (minimum to dissolve) was added thereto and the resultant light milky yellow solution was stirred overnight at room temperature. The solution was diluted with ethyl acetate and washed with water (3X). The organic layer was dried (MgSO₄), the solvent removed in vacuo, and the residue flash chromatographed over silica gel in 1:1 hexane/ethyl acetate to yield 620 mg (48%) of a white glass: NMR (DMSO-d₆) δ 7.79 (d, 1H, J=7Hz); 7.62 (t, 1H, J=7Hz); 7.55 (t, 1H, J=7Hz); 7.45 (d, 1H, J=7Hz); 7.41-7.18 (m, 9H); 7.06 (d, 2H, J=9Hz); 6.95-6.80 (m, 8H); 6.80-6.55 (m, 1H); 5.73 (d of

d,1H,J=17,3 Hz); 5.17 (s,2H); 5.10 (t,1H,J=7Hz); 5.05
 (d of d,1H,J=12,3Hz); 4.28 (d,2H,J=7Hz); 2.37
 (t,2H,J=7Hz); 1.50 (t of q,2H,J=7,7Hz); 0.78
 (t,3H,J=7Hz). IR (neat) 1029; 1006; 909; 733; 698
 5 cm⁻¹. Anal. calcd. for C₄₂H₃₈N₆O•H₂O: C, 76.34; H,
 6.10; N, 12.72. Found: C, 76.49; H, 5.88; N, 12.52.




PART H: Preparation of 2-n-propyl-1-[(2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl-4-yl)methyl]-4-vinylimidazole-5-carboxaldehyde.

5-hydroxymethyl-2-n-propyl-1-[(2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl-4-yl)methyl]-4-vinylimidazole (470 mg, 0.73 mmol, 1 eq),
 25 Dess-Martin periodinane (J. Org. Chem. (1983) **48**, 4155) (341 mg, 0.80 mmol, 1.1 eq) and methylene chloride (10mL) were mixed and stirred under nitrogen overnight. The solvent was removed in vacuo and the residue flash chromatographed in 3:2 hexane ethyl acetate over silica gel to yield 310 mg (66%) of a white glass. NMR (DMSO-d₆) δ 9.91 (s,1H); 7.80 (d,1H,J=7Hz); 7.61 (t,1H, J=7Hz); 7.54 (t,1H,J=7Hz); 7.48-7.22(m,10H); 7.20 (d,1H,J=9Hz); 7.06 (d,2H,J=9Hz); 7.00-6.75 (m,8H); 6.15
 30 (d of d,1H,J=17,3 Hz); 5.52 (s,2H); 5.47 (d of
 35

d, 1H, J=12,3 Hz); 2.49 (t, 2H, J=7Hz); 1.57 (t of q, 2H, J=7,7Hz); 0.79 (t, 3H, J=7Hz). IR (neat) 1658 cm⁻¹. Anal. calcd. for C₄₂H₃₆N₆O[•](H₂O)_{0.5}: C, 77.63; H, 5.74; N, 12.93. Found: C, 77.53; H, 5.73; N, 12.64.

5

10




15 PART I: Preparation of 2-n-propyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-vinyl-imidazole-5-carboxaldehyde.

20 2-n-propyl-1-[(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl))biphenyl-4-yl)methyl]-4-vinyl-imidazole-5-carboxaldehyde (330 mg), trifluoroacetic acid (1.65 mL), water (1.65 mL), and THF (1.65 mL) were mixed and stirred at room temperature. After 8 h, the mixture was neutralized to pH=7 with 10N NaOH and the solvents removed in vacuo. The residue was flash chromatographed in 1:1 hexane/ethyl acetate to 100% ethanol to yield 270 mg of a white glass. NMR (DMSO-d₆) δ 9.92 (s, 1H); 7.65-7.50 (m, 1H); 7.50-7.12 (m, 3H); 7.09 (d, 2H, J=9Hz); 6.89 (d, 2H, J=9Hz); 6.11 (d of d, 1H, J=17,3Hz); 5.55 (s, 2H); 5.45 (d of d, 1H, J=12,3Hz); 2.63 (t, 2H, J=7Hz); 1.64 (t of q, 2H, J=7,7Hz); 0.90 (t, 3H, J=7Hz). IR (Nujol) 1680 cm⁻¹.

114

Example 2

5



10


PART A: Preparation of 5-hydroxymethyl-4-iodo-2-n-propylimidazole.

15

20

A solution of 31.5 g of 4(5)-hydroxymethyl-2-n-propylimidazole and 50.6 g of N-iodosuccinimide in 560 mL of 1,4-dioxane and 480 mL of 2-methoxyethanol was stirred at 45°C for 2 h. The solvents then were removed under vacuum. The resulting solids were washed with distilled water and then were dried to afford 54.6 g of the product as a yellow solid; mp 169-170°C. NMR (DMSO-d₆) δ 12.06 (br s, 1H); 5.08 (t, 1H); 4.27 (d, 2H); 2.50; (t, 2H); 1.59 (sext., 2H); 0.84 (t, 3H).

25



30

PART B: Preparation of 4-iodo-2-n-propylimidazole-5-carboxaldehyde

35


To a solution of 35.8 g of 5-hydroxymethyl-4-iodo-2-n-propylimidazole in 325 mL of glacial acetic

SUBSTITUTE SHEET

acid at 20°C was added dropwise over 1 h 290 mL of 1.0 N aqueous ceric ammonium nitrate solution. The resulting mixture was stirred at 20°C for 1 h. The reaction mixture then was diluted with water, adjusted to pH 5-6 employing aqueous sodium hydroxide solution, and extracted with chloroform. The combined organic phases were washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude solid was recrystallized from 1-chlorobutane to furnish 29.9 g of product as a light yellow solid; mp 141-142°C. NMR (CDCl_3) δ 11.51 (br s, 1H); 9.43 (s, 1H); 2.81 (t, 2H); 1.81 (sext., 2H); 0.97 (t, 3H).

15

20



25

PART C: Preparation of 3-n-propyl-4-(phenylethynyl)imidazole-5-carboxaldehyde.

30

35

A solution of 2.64 g (0.01 mol) of 4-iodo-2-n-propylimidazole-5-carboxaldehyde, 25 mL of dry DMF, 2.5 mL of triethylamine, 1.00 g (0.001426 mol) of bis(triphenylphosphine)palladium chloride and 5.00 g (0.017 mol) of (phenylethynyl)tributyltin was heated to 70°C under nitrogen. The reaction was stirred for 120 hours, then cooled. The precipitate was filtered and washed with methylene chloride, and the resulting

filtrate was evaporated under reduced pressure. The

116

residue was dissolved in 200 mL of methylene chloride and extracted three times with 100 mL of 10% HCl. The aqueous layer pH was adjusted to 10 with 50% sodium hydroxide and extracted three times with 100 mL of methylene chloride. The organic phase was dried over sodium sulfate and evaporated under reduced pressure. Yield 0.56 g (0.0023 mol, 23%) of 3-n-propyl-4-(phenylethynyl)imidazole-5-carboxaldehyde. NMR (CDCl₃) δ 9.89 (s,1H); 8.22 (s,1H); 7.93 (m,3H); 7.53 (m,2H); 2.87 (t,2H); 1.87 (m,2H); 1.03 (t,3H).

15

20

25


30

35

SUBSTITUTE SHEET


The following intermediates could be prepared by the procedure described in example 2, part C:

5



10

	R ₆	R	mp (°C)
15	n-propyl	4-CF ₃	
	n-propyl	4-OMe	
	n-propyl	4-COOH	
	n-propyl	4-CON(Me) ₂	
	n-propyl	4-SO ₂ CH ₃	
	n-propyl	4-SO ₂ NMe ₂	
20	n-propyl	3-CF ₃	
	n-propyl	3-OMe	
	n-propyl	3-COOH	
	n-propyl	3-CON(Me) ₂	
	n-propyl	3-SO ₂ CH ₃	
	n-propyl	3-SO ₂ NMe ₂	
25	n-butyl	4-CF ₃	
	n-butyl	4-OMe	
	n-butyl	4-COOH	
	n-butyl	4-CON(Me) ₂	
	n-butyl	4-SO ₂ CH ₃	
30	n-butyl	4-SO ₂ NMe ₂	
	n-butyl	3-CF ₃	
	n-butyl	3-OMe	
	n-butyl	3-COOH	
	n-butyl	3-CON(Me) ₂	
	n-butyl	3-SO ₂ CH ₃	
35	n-butyl	3-SO ₂ NMe ₂	



PART D. Preparation of 4-phenylethynyl-3-n-propyl-1-
 15 [(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)
 methyl]imidazole-5-carboxaldehyde.

20 3-n-Propyl-4-(phenylethynyl)imidazole-5-
 carboxaldehyde was alkylated with 4-bromomethyl-2'-(N-
 triphenylmethyl-(1H-tetrazol-5-yl))biphenyl
 by the procedure described in example 1, parts D and I,
 to yield the entitled product. NMR (CDCl_3) δ 9.88
 (s,1H); 8.03 (m,1H); 7.57-7.27 (m,8H); 7.17 (m,2H);
 25 7.01 (m,2H); 5.55 (s,2H); 2.61 (t,2H); 1.75 (m,2H);
 0.99 (t,3H).


Examples 3-26 (Table 1) could be made by the
 procedures described in Example 2.

30

35

Table 1

5




10

Example No.	R6	R	mp (°C)
15			
3	n-propyl	4-CF ₃	
4	n-propyl	4-OMe	
5	n-propyl	4-COOH	
6	n-propyl	4-CON(Me) ₂	
7	n-propyl	4-SO ₂ CH ₃	
20	8	4-SO ₂ NMe ₂	
	9	3-CF ₃	
	10	3-OMe	
	11	3-COOH	
	12	3-CON(Me) ₂	
	13	3-SO ₂ CH ₃	
25	14	3-SO ₂ NMe ₂	
	15	4-CF ₃	
	16	4-OMe	
	17	4-COOH	
	18	4-CON(Me) ₂	
30	19	4-SO ₂ CH ₃	
	20	4-SO ₂ NMe ₂	
	21	3-CF ₃	
	22	3-OMe	
	23	3-COOH	
	24	3-CON(Me) ₂	
35	25	3-SO ₂ CH ₃	
	26	3-SO ₂ NMe ₂	

120

Example 27

5



10 PART A: Preparation of 4-(furan-2-yl)-2-n-propylimidazole-5-carboxaldehyde.

15 A solution of 2.64 g (0.01 mol) of 4-iodo-3-n-propylimidazole-5-carboxaldehyde, 60 mL of toluene, and 0.33 g (0.00029 mol) of tetrakis(triphenylphosphine) palladium (0) was stirred at room temperature under nitrogen, while a solution of 2.34 g (0.0174 mol) of furan-2-ylboronic acid in 50 mL of ethanol was slowly added. The reaction was stirred for 5 minutes, after which 12 mL of 2M sodium carbonate was slowly added. After the addition was completed, the reaction was refluxed for 8 h and cooled. The reaction was filtered, the filtrate was evaporated under reduced pressure, and the resulting residue was dissolved in 300 mL of methylene chloride, washed twice with 100 mL of saturated sodium chloride solution, washed twice with 100 mL of distilled water, and washed twice with 300 mL of 10% HCl. The HCl layer was made basic with 50% sodium hydroxide until the pH=10. At this point, the basic water layer was extracted three times with 300 mL of methylene chloride, the methylene chloride layer was dried over sodium sulfate and evaporated under reduced pressure. Yield: 0.34 g (0. 00156 mol),

35

SUBSTITUTE SHEET

121

5-carboxaldehyde. NMR (CDCl_3) δ 10.14 (s, 1H); 7.54 (s, 1H); 7.00 (d, 1H); 6.55 (m, 1H); 2.79 (t, 2H); 1.80 (m, 2H); 1.02 (t, 3H).

5 The following intermediates (Table 2) were or
could be prepared by the procedure described in Example
27, part A:

10

15

20


25

30

35

SUBSTITUTE SHEET


Table 2



	R6	R7	mp (°C)
10	n-propyl		glass ^a
15	n-propyl		wax ^b
20	n-propyl		
25	n-propyl		
30	n-propyl		
35	n-propyl		

Table 2, continued.


5



10


	R6	R7	mp (°C)
--	----	----	---------

n-propyl




15

n-propyl




20

n-propyl




25

n-propyl




30

n-propyl



35


n-propyl



124

Table 2, continued.

5




10

R6

R7


mp (°C)

n-propyl




15

n-propyl




20

n-propyl




25

n-propyl



30


n-propyl



35

Table 2, continued.

5




R6

R7

mp (°C)

10


n-propyl



15


20

n-propyl

wax^c

25

n-propyl




30

35


Table 2, continued.

5




10

n-butyl




15

n-butyl




20

n-butyl



25

n-butyl




30

n-butyl



35

n-butyl




R6

R7

mp (°C)

Table 2, continued.

5




10

R6

R7


mp (°C)

n-butyl




15

n-butyl




20

n-butyl




25

n-butyl



30

n-butyl



35

n-butyl





Table 2, continued.

5




R6

R7

mp (°C)


10

n-butyl




15

n-butyl




20

n-butyl




25

n-butyl






30

n-butyl



35


Table 2, continued.

	R6	R7	mp (°C)
10			
15	n-butyl		
20	n-butyl		
25	n-butyl		
30	<p>^aNMR (CDCl₃) δ 10.25 (s, 1H); 9.85 (s, 1H); 7.85 (m, 2H); 7.65 (m, 3H); 7.25 (m, 4H); 2.83 (t, 2H); 1.85 (m, 2H); 1.05 (t, 3H).</p> <p>^bNMR (CDCl₃) δ 11.45 (bs, 1H); 9.88 (s, 1H); 7.55 (m, 1H); 7.37 (m, 1H); 7.13 (m, 1H); 2.73 (t, 2H); 1.80 (m, 2H); 0.91 (t, 3H).</p> <p>^cNMR (DMSO-D₆) δ 9.66 (s, 1H), 7.70 (m, 1H), 7.38 (m, 2H), 7.11 (m, 2H), 7.04 (m, 4H), 2.70 (t, 2H), 1.80 (m, 2H), 0.97 (t, 3H).</p>		
35			

130

5

10



PART B: Preparation of 4-(furan-2-yl)-2-n-propyl-1-

15 [(2'-(1H-tetrazol-5-yl)biphenyl-4-
y1)methyl]imidazole-5-carboxaldehyde.

20 4-(furan-2-yl)-2-n-propylimidazole-5-
carboxaldehyde was transformed into the entitled
product by the procedures described in Example 1, parts
D and I: mp 129 (dec.). NMR (CDCl_3) δ 10.15 (s,1H);
7.95 (d,1H); 7.55 (m,2H); 7.38 (m,2H); 7.10 (d,2H);
6.98 (d,2H); 6.85 (d,1H); 6.45 (m,1H); 5.55 (s,2H);
2.55 (t,2H); 1.70 (m,2H); 0.91 (t,3H).

25 The examples in Table 3 could be prepared by
the procedures described in example 27 using the
appropriate starting materials:

30

35

Table 3

5









Example No.	R^6	R^7	mp (°C)
10	28	n-propyl	-  glass*
15	29	n-propyl	- 
20	30	n-propyl	- 
25	31	n-propyl	- 
30	32	n-propyl	- 
35	33	n-propyl	- 
	34	n-propyl	- 

Table 3, continued.

Example No.	R_6	R_7	mp (°C)
10			
35	n-propyl		
15	36	n-propyl	
20	37	n-propyl	
25	38	n-propyl	
30	39	n-propyl	
35	40	n-propyl	

Table 3, continued.

5



10

Example No.


R⁶R⁷

mp (°C)

15

41


n-propyl



20

42


n-propyl



25

43


n-propyl



30

44

n-propyl



35

45

n-propyl





Table 3, continued.

5



Example No.


R₆R₇

mp (°C)

10

46


n-propyl



15

47


n-propyl



20

48

n-propyl




25

30

35

Table 3, continued.

5



10

Example No.


R⁶R⁷

mp (°C)

15

49


n-butyl



20

50


n-butyl



25

52


n-butyl



30

53


n-butyl



35

54

n-butyl



55

n-butyl





Table 3, continued.

5



Example No.


R⁶R⁷

mp (°C)

10

56


n-butyl



15

57


n-butyl



20

58


n-butyl



25

59


n-butyl



30

60

n-butyl




35

61

n-butyl



Table 3, continued.









Example No.	R^6	R^7	mp (°C)
10			
62	n-butyl		
15			
63	n-butyl		
20			
64	n-butyl		
25			
65	n-butyl		
30			
66	n-butyl		
35			

Table 3, continued.

5



10

Example No.


R⁶R⁷

mp (°C)

15

67


n-butyl



20

68


n-butyl



25

69

n-butyl



30

35

aNMR (CDCl₃) δ 9.81 (s, 1H), 7.92 (d, 2H), 7.53 (m, 9H), 7.27 (m, 4H), 7.11 (d, 2H), 6.98 (d, 2H), 5.60 (s, 2H), 2.51 (t, 2H), 1.73 (m, 2H), 0.99(t, 3H).

bNMR (CDCl₃) δ 9.69 (s, 1H), 8.10 (m, 1H), 7.58 (m, 4H), 7.48 (m, 3H), 7.18 (d, 2H), 7.00 (m, 7H), 5.62 (s, 2H), 2.61 (t, 2H), 1.79 (m, 2H), 1.02 (t, 3H).

The examples in Tables 4 and 5 can be made by procedures described in examples 1, 2, or 27 using the biphenyl starting materials disclosed in this patent or by other methods familiar to one skilled in the art.

5

10

15


20

25

30

35

Table 4




Ex. No.	R ⁶	R	R ⁸	X	A	mp (°C)
70	n-propyl	4-CF ₃	CHO	single bond	COOH	
71	n-propyl	4-OMe	CHO	single bond	COOH	
72	n-propyl	4-COOH	CHO	single bond	COOH	
73	n-propyl	4-CON(Me) ₂	CHO	single bond	COOH	
74	n-propyl	4-SO ₂ CH ₃	CHO	single bond	COOH	
75	n-propyl	4-SO ₂ NMe ₂	CHO	single bond	COOH	
76	n-propyl	3-CF ₃	CHO	single bond	COOH	
77	n-propyl	3-OMe	CHO	single bond	COOH	
78	n-propyl	3-COOH	CHO	single bond	COOH	
79	n-propyl	3-CON(Me) ₂	CHO	single bond	COOH	
80	n-propyl	3-SO ₂ CH ₃	CHO	single bond	COOH	
81	n-propyl	3-SO ₂ NMe ₂	CHO	single bond	COOH	
82	n-butyl	4-CF ₃	CHO	single bond	COOH	
83	n-butyl	4-OMe	CHO	single bond	COOH	
84	n-butyl	4-COOH	CHO	single bond	COOH	
85	n-butyl	4-CON(Me) ₂	CHO	single bond	COOH	
86	n-butyl	4-SO ₂ CH ₃	CHO	single bond	COOH	
87	n-butyl	4-SO ₂ NMe ₂	CHO	single bond	COOH	
88	n-butyl	3-CF ₃	CHO	single bond	COOH	
89	n-butyl	3-OMe	CHO	single bond	COOH	
90	n-butyl	3-COOH	CHO	single bond	COOH	
91	n-butyl	3-SO ₂ CH ₃	CHO	single bond	COOH	
92	n-butyl	3-SO ₂ NMe ₂	CHO	single bond	COOH	

Table 4 (continued)

5


10



	Ex. No.	R ⁶	R	R ⁸	X	A	mp (°C)
15	93	n-propyl	4-CF ₃	COOH	single bond	CN4H	
	94	n-propyl	4-OMe	COOH	single bond	CN4H	
	95	n-propyl	4-COOH	COOH	single bond	CN4H	
	96	n-propyl	4-CON(Me) ₂	COOH	single bond	CN4H	
	97	n-propyl	4-SO ₂ CH ₃	COOH	single bond	CN4H	
	98	n-propyl	4-SO ₂ NMe ₂	COOH	single bond	CN4H	
20	99	n-propyl	3-CF ₃	COOH	single bond	CN4H	
	100	n-propyl	3-OMe	COOH	single bond	CN4H	
	101	n-propyl	3-COOH	COOH	single bond	CN4H	
	102	n-propyl	3-CON(Me) ₂	COOH	single bond	CN4H	
	103	n-propyl	3-SO ₂ CH ₃	COOH	single bond	CN4H	
	104	n-propyl	3-SO ₂ NMe ₂	COOH	single bond	CN4H	
25	105	n-butyl	4-CF ₃	COOH	single bond	CN4H	
	106	n-butyl	4-OMe	COOH	single bond	CN4H	
	107	n-butyl	4-COOH	COOH	single bond	CN4H	
	108	n-butyl	4-CON(Me) ₂	COOH	single bond	CN4H	
	109	n-butyl	4-SO ₂ CH ₃	COOH	single bond	CN4H	
	110	n-butyl	4-SO ₂ NMe ₂	COOH	single bond	CN4H	
30	111	n-butyl	3-CF ₃	COOH	single bond	CN4H	
	112	n-butyl	3-OMe	COOH	single bond	CN4H	
	113	n-butyl	3-COOH	COOH	single bond	CN4H	
	114	n-butyl	3-SO ₂ NMe ₂	COOH	single bond	CN4H	

Table 4 (continued)

5




10

	Ex. No.	R ⁶	R	R8	X	A	mp (°C)
15	115	n-propyl	4-CF ₃	CHO	single bond	NHSO ₂ CF ₃	
	116	n-propyl	4-OMe	CHO	single bond	NHSO ₂ CF ₃	
	117	n-propyl	4-COOH	CHO	single bond	NHSO ₂ CF ₃	
	118	n-propyl	4-CON(Me) ₂	CHO	single bond	NHSO ₂ CF ₃	
	119	n-propyl	4-SO ₂ CH ₃	CHO	single bond	NHSO ₂ CF ₃	
	120	n-propyl	4-SO ₂ NMe ₂	CHO	single bond	NHSO ₂ CF ₃	
	121	n-propyl	3-CF ₃	CHO	single bond	NHSO ₂ CF ₃	
	122	n-propyl	3-OMe	CHO	single bond	NHSO ₂ CF ₃	
	123	n-propyl	3-COOH	CHO	single bond	NHSO ₂ CF ₃	
	124	n-propyl	3-CON(Me) ₂	CHO	single bond	NHSO ₂ CF ₃	
20	125	n-propyl	3-SO ₂ CH ₃	CHO	single bond	NHSO ₂ CF ₃	
	126	n-propyl	3-SO ₂ NMe ₂	CHO	single bond	NHSO ₂ CF ₃	
	127	n-butyl	4-CF ₃	CHO	single bond	NHSO ₂ CF ₃	
	128	n-butyl	4-OMe	CHO	single bond	NHSO ₂ CF ₃	
	129	n-butyl	4-COOH	CHO	single bond	NHSO ₂ CF ₃	
	130	n-butyl	4-CON(Me) ₂	CHO	single bond	NHSO ₂ CF ₃	
25	131	n-butyl	4-SO ₂ CH ₃	CHO	single bond	NHSO ₂ CF ₃	
	132	n-butyl	4-SO ₂ NMe ₂	CHO	single bond	NHSO ₂ CF ₃	
	133	n-butyl	3-CF ₃	CHO	single bond	NHSO ₂ CF ₃	
	134	n-butyl	3-OMe	CHO	single bond	NHSO ₂ CF ₃	
	135	n-butyl	3-COOH	CHO	single bond	NHSO ₂ CF ₃	
	136	n-butyl	3-SO ₂ NMe ₂	CHO	single bond	NHSO ₂ CF ₃	
30	137	n-butyl	4-CF ₃	CHO	single bond	NHSO ₂ CF ₃	
	138	n-butyl	4-OMe	CHO	single bond	NHSO ₂ CF ₃	
	139	n-butyl	4-COOH	CHO	single bond	NHSO ₂ CF ₃	
	140	n-butyl	4-CON(Me) ₂	CHO	single bond	NHSO ₂ CF ₃	
	141	n-butyl	4-SO ₂ CH ₃	CHO	single bond	NHSO ₂ CF ₃	
	142	n-butyl	4-SO ₂ NMe ₂	CHO	single bond	NHSO ₂ CF ₃	

35

Table 4 (continued)


5



10

	Ex. No.	R ⁶	R	R ⁸	X	A	mp (°C)
15	137	n-propyl	4-CF ₃	CHO	-NHCO-	CN4H	
	138	n-propyl	4-OMe	CHO	-O-	CN4H	
	139	n-propyl	4-COOH	CHO	-S-	CN4H	
	140	n-propyl	4-CON(Me) ₂	CHO	-NH-	CN4H	
	141	n-propyl	4-SO ₂ CH ₃	CHO	-OCH ₂ -	CN4H	
	142	n-propyl	4-SO ₂ NMe ₂	CHO	-SCH ₂ -	CN4H	
	143	n-propyl	3-CF ₃	CHO	-CH ₂ O-	CN4H	
	144	n-propyl	3-OMe	CHO	-NHSO ₂ -	CN4H	
	145	n-propyl	3-COOH	CHO	-SO ₂ NH	CN4H	
	146	n-propyl	3-CON(Me) ₂	CHO	-CH=CH-	CN4H	
20	147	n-propyl	3-SO ₂ CH ₃	CHO	-CO-	CN4H	
	148	n-propyl	3-SO ₂ NMe ₂	CHO	-CH ₂ -	CN4H	
25	149	n-butyl	4-CF ₃	CHO	-NHCO-	CN4H	
	150	n-butyl	4-OMe	CHO	-O-	CN4H	
	151	n-butyl	4-CON(Me) ₂	CHO	-S-	CN4H	
	152	n-butyl	4-SO ₂ CH ₃	CHO	-NH-	CN4H	
	153	n-butyl	4-SO ₂ NMe ₂	CHO	-CH ₂ S-	CN4H	
	154	n-butyl	3-CF ₃	CHO	-SCH ₂ -	CN4H	
	155	n-butyl	3-OMe	CHO	-SO ₂ NH-	CN4H	
	156	n-butyl	3-COOH	CHO	-CO-	CN4H	
	157	n-butyl	3-SO ₂ NMe ₂	CHO	-CH ₂ -	CN4H	

Table 5




5

Ex. No.	R ⁶	R ⁷	R ⁸	A	mp (°C)
---------	----------------	----------------	----------------	---	---------

10


158 n-propyl



COOH single bond CN4H

15


159 n-propyl



COOH single bond CN4H

20


160 n-propyl



COOH single bond CN4H

25


161 n-propyl



COOH single bond CN4H

30


162 n-propyl



COOH single bond CN4H


35

163 n-propyl



COOH single bond CN4H

164 n-propyl



COOH single bond CN4H


Table 5 (continued)

Ex. No.	R ₆			A	mp (°C)
		R ₇	R ₈		
10					
165	n-propyl		CHO	single bond	COOH
166	n-propyl		CHO	single bond	COOH
167	n-propyl		CHO	single bond	COOH
168	n-propyl		CHO	single bond	COOH
169	n-propyl		CHO	single bond	COOH
170	n-propyl		CHO	single bond	COOH

35

Table 5 (continued)

5



10

Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
---------	----------------	----------------	----------------	---	---------

15

171 n-propyl CHO single bond NHSO_2CF_3

20

172 n-propyl CHO single bond NHSO_2CF_3

25

173 n-propyl CHO single bond NHSO_2CF_3

30

174 n-propyl CHO single bond NHSO_2CF_3

35


175 n-propyl CHO single bond NHSO_2CF_3

Table 5 (continued)

Ex. No.	R ⁶				A	mp (°C)
		R ⁷	R ⁸	X		
10						
15	176 n-propyl		CHO	-NHCO-	CN4H	
20	177 n-propyl		CHO	-O-	CN4H	
25	178 n-propyl		CHO	-S-	CN4H	
30	179 n-propyl		CHO	-CO-	CN4H	
35	180 n-propyl		CHO	-OCH2-	CN4H	
	181 n-propyl		CHO	-CH=CH-	CN4H	

Table 5 (continued)

5



Ex. No. R6

R7

R8


X

A mp (°C)

10

15


182 n-propyl



CHO single bond CN4H

20


183 n-propyl



CHO single bond CN4H

25


184 n-propyl



CHO single bond CN4H

30

185 n-propyl



CHO single bond CN4H


35

Table 5 (continued)

Ex. No.	R^6	R^7	R^8	X	A	mp (°C)
						10
15	186 n-propyl		CHO	single bond	CN4H	
20	187 n-propyl		CHO	single bond	CN4H	
25	188 n-propyl		CHO	single bond	CN4H	
30	189 n-propyl		CHO	single bond	CN4H	
35						

Table 5 (continued)

5



10

Ex. No.	R ⁶	R ⁷	R ⁸	A	mp (°C)
---------	----------------	----------------	----------------	---	---------

15

190 n-propyl CHO single bond CN4H

20

191 n-propyl CHO single bond CN4H

25

192 n-propyl CHO single bond CN4H

30

193 n-propyl CHO single bond CN4H


35

Table 5 (continued)

Ex. No.	R^6	R^7	R^8	A	mp (°C)
10					
15	194 n-propyl		CHO	single bond	CN4H
20	195 n-propyl		CHO	single bond	CN4H
25	196 n-propyl		COOH	single bond	CN4H
30	197 n-propyl		COOH	single bond	CN4H
35					

Table 5 (continued)

5



Ex. No.

R⁶R⁷R⁸


X

A

mp (°C)


10

198 n-propyl

CH₂OH single bond CN4H


15

199 n-propyl

CH₂OH single bond CN4H


20

200 n-propyl

CH₂OH single bond CN4H


25

201 n-propyl

CH₂OH single bond CN4H


30

202 n-propyl

CH₂OH single bond CN4H

35

203 n-propyl

CH₂OH single bond CN4H

204 n-propyl


CH₂OH single bond CN4H

Table 5 (continued)





Ex. No.	R ₆	R ₇	R ₈	X	A	mp (°C)
205	n-propyl	$\xi\text{-C}\equiv\text{C-H}$		CHO single bond	CN4H	
206	n-propyl	$\xi\text{-C}\equiv\text{C-CH}_3$		CHO single bond	CN4H	
207	n-propyl	$\xi\text{-C}\equiv\text{C-CH}_2\text{-CH}_3$		CHO single bond	CN4H	
208	n-propyl	$\xi\text{-C}\equiv\text{C-CH}_2\text{-Ph}$		CHO single bond	CN4H	
209	n-propyl	$-(\text{CH}_2)\text{-}$ 		CHO single bond	CN4H	
210	n-propyl	$-\text{CH}=\text{CH-}$ 		CHO single bond	CN4H	
211	n-propyl	$-\text{CH}_2\text{-CH=CH-}$ 		CHO single bond	CN4H	
212	n-propyl	$\xi\text{-C}\equiv\text{C-}$ 		CHO single bond	CN4H	

Table 5 (continued)







Ex. No.	R^6	R^7	R^8	X	A	$mp\ (^{\circ}C)$
10						
213	n-propyl				CHO single bond	CN4H
15	214	n-propyl			CHO single bond	CN4H
20	215	n-propyl			CHO single bond	CN4H
25	216	n-propyl			CHO single bond	CN4H
30	217	n-propyl			CHO single bond	CN4H
35	218	n-propyl			CHO single bond	CN4H
	219	n-propyl			CHO single bond	CN4H

Table 5 (continued)


5



Ex. No.	R ⁶	R ⁷	R ⁸	X	A	mp (°C)
---------	----------------	----------------	----------------	---	---	---------

15

220 n-propyl -CH₂-CH=CH-



CHO single bond CN4H

20


25

30

35

The following compounds in Table 6 were prepared or could be prepared by the procedure in example 1:

Table 6



Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
221	n-butyl		cis	CHO	CN ₄ H
222	n-butyl		cis	CHO	CN ₄ H
223	n-butyl			CHO	CN ₄ H
224	n-butyl			CHO	CN ₄ H
225	n-butyl			CHO	CN ₄ H

157
Table 6, continued.








Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
226	n-butyl		CHO	CN ₄ H	
227	n-propyl		CHO	CN ₄ H	
228	n-propyl		CHO	CN ₄ H	
229	n-propyl		CHO	CN ₄ H	
230	n-propyl		COOH	CN ₄ H	
231	n-propyl		CHO	COOH	
232	n-propyl		COOH	CN ₄ H	

Table 6, continued.











Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
233	n-propyl			CH ₂ OH	CN ₄ H
234	n-butyl			CH ₂ OH	CN ₄ H
235	n-butyl			COOH	CN ₄ H
236	n-propyl			CHO	CN ₄ H
237	n-propyl			COOH	-NHSO ₂ CF ₃
238	n-propyl			CHO	COOH

Table 6, continued.

Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
239	n-propyl			CHO	CN ₄ H
240	n-propyl			CHO	COOH
241	n-butyl			CHO	CN ₄ H

Example 242

5



10

15

Preparation of 2-n-Butyl-4-phenylthio-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole-5-carboxyaldehyde

20

2-n-Butyl-4-chloro-1-[(2'-N-triphenyl-methyl(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxyaldehyde (synthesized as described in European Patent Application Number 89100144.8, published 7.19.89) (590 mg, 0.89 mmol, 1 eq), and thiophenol (0.91 mL, 8.9 mmol, 10 eq) were added to a freshly prepared solution of sodium methoxide in methanol (sodium: 205 mg, 8.9 mmol, 10 eq; methanol, 40 mL) and the mixture refluxed overnight under N₂. The solvent was removed in vacuo and the residue dissolved in water (50 mL). The pH was adjusted to 10-12 with 10 N NaOH. Gummy solids (trityl group-containing compound) formed which were dissolved by the addition of ethyl ether (50 mL). The layers were separated and the aqueous layer extracted with ethyl ether (2 x 50

25

30


35

mL). The aqueous layer was then extracted with ethyl acetate (6 x 50 mL). The ethyl acetate layers were collected, dried ($MgSO_4$), and the solvent removed in vacuo to yield a residue which was redissolved in water (50 mL). The pH was adjusted to 1 with conc. HCl. A gummy precipitate containing product formed which was dissolved in ethyl acetate (50 mL). The layers were separated and the aqueous layer was extracted with ethyl acetate (2 x 50 mL). The ethyl acetate layers were collected, dried ($MgSO_4$), and the solvent removed in vacuo to yield a white glass (200 mg).

Crystallization from hot n-butylchloride yielded a white solid (142 mg): mp 1435-145.5°C. NMR ($DMSO-d_6$) δ 9.82 (s, 1H); 7.80-7.61 (m, 2H); 7.58 (d, 1H, $J=8Hz$); 7.52 (d, 1H, $J=8Hz$); 7.45-7.20 (m, 5H); 7.09 (d, 1H, $J=8Hz$); 7.03 (d, 2H, $J=8Hz$); 5.62 (s, 2H); 2.64 (t, 2H, $J=7Hz$); 1.50 (t of t, 1H, $J=7,7Hz$); 1.25 (t of q, 2H, $J=7,7Hz$); 0.80 (t, 3H, $J=7Hz$). Anal. calcd. for $CC_{28}H_{26}N_6OS \cdot (H_2O)_{0.4}$: C, 67.02; H, 5.38; N, 16.75; S, 6.39. Found: C, 66.90; H, 5.20; N, 16.75; S, 6.00.


Examples 243-253 in Table 7 can be made by procedures described in example 242 and other examples in this patent application and in EP 89100144.8 (published 7.19.89) or by other methods familiar to one skilled in the art.

Table 7



Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
243	n-butyl		CHO	COOH	142.5-143.5
244	n-butyl	CHO		COOH	a
245	n-butyl		CHO	CN ₄ H	b
246	n-butyl		CHO	COOH	c
247	n-butyl		CHO	CN ₄ H	
248	n-butyl		CHO	CN ₄ H	


Table 7 (continued)



Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
249	n-propyl	-NHCOCH ₃		CHO	CN ₄ H
250	n-propyl	CHO		NHSO ₂ CF ₃	CN ₄ H
251	n-propyl			CHO	COOH
252	n-propyl			COOH	COOH
253	n-propyl			CH ₂ OH	COOH
254	n-propyl			CH ₂ OH	CN ₄ H


164

Table 7 (continued)



Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
255	n-propyl			CHO COOH	
256	n-butyl			CHO CN4H	
257	n-butyl			CHO CN4H	
258	n-butyl			CH ₂ OH CN4H	




Table 7 (continued)



Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
259	n-propyl			CHO COOH	
260	n-propyl			CHO CN4H	
261	n-butyl			CHO CN4H	
262	n-butyl			CHO CN4H	
263	n-butyl			CHO CN4H	
264	n-propyl			CHO CN4H	

Table 7 (continued)

Ex. No.	R ₆	R ₇	R ₈	A	mp (°C)
---------	----------------	----------------	----------------	---	---------




aNMR (DMSO-d₆) δ 9.97 (s, 1H); 7.59 (d, 1H, J=8Hz); &.50-7.10 (m, 8H); 7.14 (d, 2H, J=8Hz); 6.91 (d, 2H, J=8Hz); 5.32 (s, 2H); 2.66 (t, 2H, J=7Hz); 1.58 (t of t, 2H, J=7,7Hz); 1.28 (t of q, 2H, J=7,7Hz); 0.82 (t, 3H, J=7Hz).

bNMR (DMSO-d₆) δ 9.80 (s, 1H); 8.41 (d, 1H, J=7Hz); 7.72 (d, 1H, J=7Hz); 7.55 (d, 1H, J=7Hz); 7.49-7.25 (m, 3H); 7.19 (t, 2H, J=7Hz); 7.09 (d, 2H, J=7Hz); 6.95 (d, 2H, J=7Hz); 5.63 (s, 2H); 2.70 (t, 2H, J=7Hz); 1.57 (t of t, 2H, J=7,7Hz); 1.29 (t of q, 2H, J=7,7Hz); 0.81 (t, 3H, J=7Hz).

cNMR (DMSO-d₆) δ 9.83 (s, 1H); 7.72 (d, 1H, J=8Hz); 7.65-7.15 (m, 9H); 7.10 (d, 2H, J=8Hz); 5.64 (s, 2H); 2.64 (t, 2H, J=7Hz); 1.50 (t of t, 2H, J=7,7Hz); 1.23 (t of q, 2H, J=7,7Hz); 0.78 (t, 3H, J=7Hz).

Example 268

5



10


15

PART A: Preparation of 2-n-propyl-4-cyclobutylidenyl-5-hydroxymethyl-1-[{(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl))biphenyl-4-yl}methyl]imidazole.

(δ -Bromo-n-butyl)triphenylphosphonium bromide (7.42 g, 0.0155 mmol, 2 eq) was suspended in THF (125 mL) and 0.75 M potassium hexamethyldisilazane (41.4 mL, 0.031 mmol, 4 eq) was added at room temperature. The mixture turned blood red. After 0.5 h, 2-n-propyl-5-hydroxymethyl-1-[{(2'-(N-triphenylmethyl)-(1H-tetrazol-5-yl))biphenyl-4-yl-methyl}]imidazole-4-carboxaldehyde (5.00 g, 7.75 mmol, 1 eq) as a slurry in THF was added. The mixture eventually turned into a yellow-orange suspension. After 24 h, the reaction was worked up by adding a little methanol to quench, followed by ethyl acetate and water. The layers were separated and the organic layer was washed with water (2X) and brine (1X). The organic layer was dried ($MgSO_4$), and solvent removed in vacuo, and the residue flash chromatographed in 60:40 pentane/ethyl acetate to 100% ethyl acetate to yield 4.12 g (78%) of a white solid: mp 181.5-182.5°C. NMR ($DMSO-d_6$) δ 7.78 (m, 1H); 7.61 (t, 1H, J=7Hz); 7.54 (t, 1H, J=7Hz); 7.48-7.20 (m, 10H); 7.03

(d,2H,J=8Hz); 6.96-6.70 (m,8H); 5.99 (s,1H); 5.13
(s,2H); 4.97 (t,1H,J=7Hz); 4.21 (d,2H,J=7Hz); 3.05
(m,2H); 2.79 (m,2H); 2.31 (t,2H,J=7Hz); 1.98 (m,2H);
1.48 (t of q, 2H,J=7,7Hz); 0.77 (t,3H,J=7Hz). Anal.
5 ((C₄₅H₄₂N₆O•(H₂O)0.75) C, H, N.

10



15

20

PART B: Preparation of 2-n-propyl-4-cyclobutylidenyl-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole.

25

30

35

2-n-Propyl-4-cyclobutylidenyl-5-hydroxymethyl-1-[(2'-(N-triphenylmethyl-(1H-tetrazol-5-yl))biphenyl-4-yl)methyl]imidazole (1.00 g), methanol (25 mL) and THF (15 mL) were mixed and refluxed for 24 h. The solvents were removed in vacuo and the residue immediately flash chromatographed quickly in 1:1 pentane/ethyl acetate to 100% isopropanol and eventually to 100% ethanol to yield 320 mg of a light yellow glass: NMR (DMSO-d₆) δ 7.59 (d,1H,J=7Hz); 7.54 (t,1H,J=7Hz); 7.46 (t,1H,J=7Hz); 7.42 (d,1H,J=7Hz); 7.06 (d,2H,J=7Hz); 6.90 (d,2H,J=7Hz); 5.97 (s,1H); 5.17 (s,2H); 4.31 (s,2H); 3.04 (m,2H); 2.77 (m,2H); 2.42 (t,2H,J=7Hz); 1.97 (m,2H); 1.53 (t of q,2H,J=7,7Hz); 0.86 (t 3H,J=7Hz). Anal. (C₂₆H₂₈N₆O) C, H, N.

Utility

The hormone angiotensin II (AII) produces numerous biological responses (e.g. vasoconstriction) through stimulation of its receptors on cell membranes.

5 For the purpose of identifying compounds such as AII antagonists which are capable of interacting with the AII receptor, a ligand-receptor binding assay was utilized for the initial screen. The assay was carried out according to the method described by [Glossmann et al., *J. Biol. Chem.*, **249**, 825 (1974)], but with some modifications. The reaction mixture contained rat adrenal cortical microsomes (source of AII receptor) in Tris buffer and 2 nM of ^3H -AII with or without potential AII antagonist. This mixture was incubated

10 for 1 hour at room temperature and the reaction was subsequently terminated by rapid filtration and rinsing through glass micro-fibre filter. Receptor-bound ^3H -AII trapped in filter was quantitated by scintillation counting. The inhibitory concentration (IC_{50}) of

15 potential AII antagonist which gives 50% displacement of the total specifically bound ^3H -AII is a measure of the affinity of such compound for the AII receptor. Compounds of this invention which were tested in this binding assay exhibited IC_{50} of 10^{-5}M or less (Table

20 8).

25

170

Table 8

Angiotensin II Antihypertensive

	Receptor Binding	Effects in renal Hypertensive Rats
--	------------------	------------------------------------

5	Ex. No.	IC ₅₀ (μ molar)	Intravenous Activity ¹	Oral Activity ²
	1	0.013	+	+
	2	0.021	+	NT ³
	27	0.17	+	NT ³
	28	0.35	NA	NT
10	47	0.21	NA	NT
	242	0.024	+	+
	243	0.28	NA	NT
	244	0.37	NA	NT
	245	0.024	+	+
	246	0.27	+	NT
	268	0.044	NT	NT

15

1 Significant decrease in blood pressure at 3.0 mg/kg or less

2 Significant decrease in blood pressure at 30 mg/kg or less

20 NA - Not active at 3 mg/kg or 30 mg/kg dosage tested. Although some of the compounds tested were not active orally, they were active intravenously.

NT Not tested.

NT³ Not tested at 30 mg/kg p.o.

25

30

35

The potential antihypertensive effects of the compounds of this invention may be demonstrated by administering the compounds to awake rats made hypertensive by ligation of the left renal artery

5 [Cangiano et al., J. Pharmacol. Exp. Ther., 208, 310 (1979)]. This procedure increases blood pressure by increasing renin production with consequent elevation of AII levels. Compounds are administered orally at 30 mg/kg and/or intravenously via a cannula in the jugular

10 vein at 3 mg/kg. Arterial blood pressure is continuously measured directly through a carotid artery cannula and recorded using a pressure transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels to determine the

15 antihypertensive effects of the compounds which were tested. Some compounds of this invention exhibited intravenous activity at 3 mg/kg and some exhibited oral activity at 30 mg/kg (Table 8).

Dosage Forms

20 The compounds of this invention can be administered for the treatment of hypertension according to the invention by any means that effects contact of the active ingredient compound with the site of action in the body of a warm-blooded animal. For example, administration can be parenteral, i.e., subcutaneous, intravenous, intramuscular, or intra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.

25

30 The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination of therapeutic agents. They can be administered alone, but are generally administered with a pharmaceutical carrier selected on

the basis of the chosen route of administration and standard pharmaceutical practice.

For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom
5 possessed of a homeostatic mechanism and includes mammals and birds.

The dosage administered will be dependent on the age, health and weight of the recipient, the extent of disease, kind of concurrent treatment, if any,
10 frequency of treatment and the nature of the effect desired. Usually, a daily dosage of active ingredient compound will be from about 1-500 milligrams per day. Ordinarily, from 10 to 100 milligrams per day in one or more applications is effective to obtain desired
15 results. These dosages are the effective amounts both for treatment of hypertension and for treatment of congestive heart failure, i.e., for lowering blood pressure and for correcting the hemodynamic burden on the heart to relieve the congestion.

20 The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs, syrups, and suspensions. It can also be administered parenterally, in sterile liquid dosage forms.

25 Gelatin capsules contain the active ingredient and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can
30 be manufactured as sustained release products to provide for continuous release of medication over a period of hours. Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric

coated for selective disintegration in the gastrointestinal tract.

Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.

In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.

Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents. Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.

Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field.

Useful pharmaceutical dosage-forms for administration of the compounds of this invention can be illustrated as follows:

Capsules

A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 milligrams of powdered active ingredient, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.

Soft Gelatin Capsules

A mixture of active ingredient in a digestible oil such as soybean oil, cottonseed oil or olive oil is prepared and injected by means of a positive

displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredient. The capsules are washed and dried.

Tablets

5 A large number of tablets are prepared by conventional procedures so that the dosage unit is 100 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose,
10 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.

Injectable

15 A parenteral composition suitable for administration by injection is prepared by stirring 1.5% by weight of active ingredient in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.

Suspension

20 An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredient, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol
25 solution, U.S.P., and 0.025 milliliters of vanillin.

The same dosage forms can generally be used when the compounds of this invention are administered stepwise in conjunction with another therapeutic agent. When the drugs are administered in physical
30 combination, the dosage form and administration route should be selected for compatibility with both drugs. Suitable dosages, dosage forms and administration routes are illustrated in the following tables.

Examples of NSAID's that can be combined
with AII blockers of this invention:

		Dose		
	5	Drug	(mg)	<u>Formulation</u> <u>Route</u>
		Indomethacin	25 (2/3 times daily)	Tablet Oral
10		Meclofenamate	50-100 (2/3 times daily)	Tablet Oral
		Ibuprofen	300-400 (3/4 times daily)	Tablet Oral
15		Piroxicam	10-20 (1/2 times daily)	Tablet Oral
		Sulindac	150-200 (2 times daily)	Tablet Oral
20		Azapropazone	200-500 (3/4 times daily)	Tablet Oral

25

30

35

Examples of diuretics that can be combined
with AII blockers of this invention:

		Dose	
	<u>Drug</u>	<u>(mg)</u>	<u>Formulation Route</u>
5	Benzothiadizides (e.g. hydrochlorothiazide)	25-100 (daily) Tablet	Oral
10	Loop diuretics (e.g. furosemide)	50-80 (daily) Tablet	Oral

When used with an NSAID, the dosage of AII blockers will generally be the same as when the AII blocker is used alone, i.e., 1-500 milligrams per day, ordinarily from 10 to 100 milligrams per day in one or more applications. When used with diuretics, the initial dose of AII blocker can be less, e.g., 1-100 milligrams per day and for the more active compounds 1-10 milligrams per day.

It is expected that the compounds of this invention will also be useful in the treatment of chronic renal failure.

25


30

35

CLAIMS:

1. An antihypertensive compound of the formula:

5



10

15

(I)

wherein

20

R^1 is $4-CO_2H$; $4-CO_2R^9$; $-O-S(=O)(=O)-OH$; $-SO_3H$;






25

$-C(CF_3)_2OH$; $-O-P(OH)(=O)-OH$; $-PO_3H_2$; $-NH-P(OH)(=O)-OH$;


$4-NHSO_2CH_3$; $4-NHSO_2CF_3$; $-CONHOR^{12}$;

30

$-SO_2NH_2$; $-C(OH)(R^{27})-P(OH)(=O)-OH$; $3-\begin{array}{c} N \\ || \\ C \\ || \\ N-H \end{array}$;



R^2 is H; Cl; Br; I; F; NO_2 ; CN; alkyl of 1 to 4 carbon atoms; acyloxy of 1 to 4 carbon atoms; alkoxy of 1 to 4 carbon atoms; CO_2H ; CO_2R^9 ; NHSO_2CH_3 ; NHSO_2CF_3 ;



5 R³ is H; Cl, Br, I or F; alkyl of 1 to 4 carbon atoms
or alkoxy of 1 to 4 carbon atoms;

R⁴ is CN, NO₂ or CO₂R¹¹;

R⁵ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of
3 to 6 carbon atoms, alkenyl or alkynyl of 2 to 4
carbon atoms;

10 R⁶ is alkyl of 2 to 10 carbon atoms, alkenyl or alkynyl
of 3 to 10 carbon atoms or the same groups
substituted with F or CO₂R¹⁴; cycloalkyl of 3 to 8
carbon atoms, cycloalkylalkyl of 4 to 10 carbon
atoms; cycloalkylalkenyl or cycloalkylalkynyl of 5
15 to 10 carbon atoms; (CH₂)_sZ(CH₂)_mR⁵ optionally
substituted with F or CO₂R¹⁴; benzyl or benzyl
substituted on the phenyl ring with 1 or 2 halogens,
alkoxy of 1 to 4 carbon atoms, alkyl of 1 to 4
20 carbon atoms or nitro;

R⁷ is vinyl; cycloalkyldienyl; alkynyl of 2-10 carbon
atoms; phenylalkynyl where the alkynyl portion is 2-
25 6 carbon atoms; heteroaryl selected from 2- and 3-
thienyl, 2- and 3-furyl, 2-, 3-, and 4-pyridyl, 2-
pyrazinyl, 2-, 4-, and 5-pyrimidinyl, 3- and 4-
pyridazinyl, 2-, 4- and 5-thiazolyl, 2-, 4-, and 5-
30 selenazolyl, and 2-, 4-, and 5-oxazolyl, 2- or 3-
pyrrolyl, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-
imidazolyl; o-, m- or p-biphenyl; o-, m- or p-
phenoxyphenyl; 2-oxazolinyl; 2-thiazolinyl;
35 substituted phenylalkynyl, heteroaryl, biphenyl or
phenoxyphenyl as defined above substituted with 1 or
2 substituents selected from halogen, hydroxy,
mercapto, alkoxy of 1-5 carbon atoms, alkyl of 1-5
carbon atoms, -NO₂, -CN, -CF₃, -COR¹⁶, -CH₂OR¹⁷,

-NHCOR¹⁷, -CONR¹⁸R¹⁹, S(O)_rR¹⁷, and SO₂NR¹⁸R¹⁹;
 pyrrolyl, pyrazolyl or imidazolyl as defined above
 substituted on ring nitrogen with alkyl of 1-5
 carbon atoms, phenyl or benzyl; or substituted
 5 alkyl, alkenyl, or alkynyl of 1 to 10 carbon atoms
 substituted with a substituted or unsubstituted
 heteroaryl, biphenylyl or phenoxyphenyl group as
 defined above; -S(O)_r-heteroaryl, -S-(O)_r-
 10 biphenylyl, -S(O)_r-phenoxyphenyl, -S-tetrazole,
 -S(O)_rR¹⁷, -NR¹⁸R¹⁹, -NR¹⁸-heteroaryl, -NR¹⁸-phenyl,
 -NR¹⁸-biphenylyl, -NR¹⁸-phenoxyphenyl, -N-
 phthalimido, -NH-SO₂-phenoxyphenyl, -NH-SO₂-
 15 heteroaryl, -NH-SO₂-biphenylyl, -NH-SO₂-R¹⁷, and
 -S-(C=O)-R¹⁷, N-imidazolyl, N-1,2,3-triazolyl,
 N-1,2,4-triazolyl, where heteroaryl is a heterocycle
 defined in the scope of R⁷ and where the phenyl
 group in R¹⁷ of -S-(O)_rR¹⁷, the N-imidazolyl, N-
 20 1,2,3-triazolyl, and N-1,2,4-triazolyls may be
 substituted with one or two substituents as
 described above for heteroaryl;


R^8 is $-(CH_2)_{n-1}CH-$
 25 $\begin{array}{c} O \\ | \\ OR^{17} \end{array}$ R¹¹; $-(CH_2)_nOCR^{14}$; $-(CH_2)_nSR^{15}$;

$\begin{array}{c} R^{14} \\ | \\ -CH=CH(CH_2)_sCHOR^{15} \end{array}$; $\begin{array}{c} O \\ | \\ -CH=CH(CH_2)_sCR^{16} \end{array}$; $\begin{array}{c} O \\ || \\ CR^{16} \end{array}$;

$\begin{array}{c} O \\ || \\ -CH=CH(CH_2)_sOCR^{11} \end{array}$; $-(CH_2)_m$ -tetrazolyl;

$(CH_2)_s-CH-$
 35 $\begin{array}{c} O \\ | \\ CH_3 \end{array}$ COR¹⁶; $-(CH_2)_n\begin{array}{c} O \\ || \\ CR^{16} \end{array}$; $-(CH_2)_n\begin{array}{c} O \\ || \\ CNHR^{10} \end{array}$;

$-(CH_2)_nNR^{11}\begin{array}{c} O \\ || \\ COR^{10} \end{array}$; $-(CH_2)_nNR^{11}\begin{array}{c} O \\ || \\ CNHR^{10} \end{array}$; $-(CH_2)_nNR^{11}SO_2R^{10}$;



5 R²⁴
 |
 O
 ||
 R⁹ is -CH-O-CR²¹:

R^{10} is alkyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 6 carbon atoms, 1-adamantyl, 1-naphthyl, 1-(1-naphthyl)ethyl, or $(CH_2)_pC_6H_5$:

10 R¹¹ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R^{12} is H, methyl or benzyl:

R^{13} 1s -CO₂H; -CO₂R⁹; -CH₂CO₂H, -CH₂CO₂R⁹; or

$$15 \quad \begin{array}{c} 0 \\ \parallel \\ -\text{C}-\text{NHSO}_2-(\text{CH}_2)_s-\text{C}_6\text{H}_3\text{R}^{20} \end{array}$$

$$-\overset{\text{O}}{\underset{\text{S}}{\text{:}}} \text{-OH}; -\overset{\text{O}}{\underset{\text{P}}{\text{:}}} \text{-OH}; -\text{SO}_3\text{H}; -\overset{\text{O}}{\underset{\text{NHP}}{\text{:}}} \text{-OH}$$

-PO₃H₂; -C(F₃)₂OH; -NHSO₂CH₃; -NHSO₂CF₃; -NHCOCF₃;

$$-\text{CONHOR}^{12}; -\text{SO}_2\text{NH}_2; \quad \begin{array}{c} \text{OH} & \text{O} \\ | & \parallel \\ -\text{C}- & \text{P}-\text{OH} \\ | & \text{OH} \\ \text{R}^{27} & \end{array}; \quad \begin{array}{c} \text{N}=\text{N} \\ || \\ \text{C}=\text{N} \\ || \\ \text{N}=\text{N} \\ \text{N}^{31} \end{array};$$

25

-CH₂-imidazole : -CONH-imidazole ; -CONHNHSO₂CF₃ ;

30

$$\text{CF}_3 \quad : \quad \begin{array}{c} \text{N}=\text{N} \\ | \quad | \\ \text{C}=\text{C}-\text{NH} \\ | \quad | \\ \text{R} \end{array}$$

35


R¹⁴ is H, alkyl or perfluoroalkyl of 1 to 8 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

5 R¹⁵ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl, benzyl, acyl of 1 to 4 carbon atoms, phenacyl;

R¹⁶ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, (CH₂)_pC₆H₅, OR¹⁷, or NR¹⁸R¹⁹;

10 R¹⁷ is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of 3 to 6 carbon atoms, phenyl or benzyl;

R¹⁸ and R¹⁹ independently are H, alkyl of 1 to 4 carbon atoms, phenyl, benzyl, *a*-methylbenzyl, or taken together with the nitrogen form a ring of the formula



Q is NR²⁰, O or CH₂;

R²⁰ is H, alkyl of 1-4 carbon atoms, or phenyl;

20 R²¹ is alkyl of 1 to 6 carbon atoms, -NR²²R²³, or -CHCH₂CO₂CH₃;
|
NH₂

25 R²² and R²³ independently are H, alkyl of 1 to 6 carbon atoms, benzyl, or are taken together as (CH₂)_u where u is 3-6;

R²⁴ is H, CH₃ or -C₆H₅:

30 R²⁵ is NR²⁷R²⁸, OR²⁸, NHCONH₂, NHCSNH₂,



35 R²⁶ is hydrogen, alkyl with from 1 to 6 carbon atoms, benzyl, or allyl;

R²⁷ and R²⁸ are independently hydrogen, alkyl with from 1 to 5 carbon atoms, or phenyl;

R²⁹ and R³⁰ are independently alkyl of 1-4 carbon atoms or taken together are -(CH₂)_q-;

R³¹ is H, alkyl of 1 to 4 carbon atoms, -CH₂CH=CH₂ or -CH₂C₆H₄R³²;

5 R³² is H, NO₂, NH₂, OH or OCH₃;

X is a carbon-carbon single bond, -CO-, -CH₂-, -O-, -S-, -NH-, -N- , -CON- , -NCO-, -OCH₂-, -CH₂O-,
 | | |
 R²⁶ R²³ R²³

10 -SCH₂-, -CH₂S-, -NHC(R²⁷)(R²⁸)-, -NR²³SO₂-,
 -SO₂NR²³-, -C(R²⁷)(R²⁸)NH-, -CH=CH-, -CF=CF-,
 -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-.



15 OR¹⁴ OCOR¹⁷ NR²⁵ R²⁹O OR³⁰
 | | " \ /
 -CH- , -CH- , -C- or -C- ;

Y is O or S;

Z is O, NR¹¹, or S;

m is 1 to 5;

20 n is 1 to 10;

p is 0 to 3;

q is 2 to 3;

r is 0 to 2;

s is 0 to 5;


25 t is 0 or 1;

or a pharmaceutically acceptable salt thereof;

provided that:

30 (1) the R¹ group is not in the ortho position;

(2) when R¹ is X-, X is a single bond,

and R^{13} is CO_2H , or , then R^{13} must:

5

be in the ortho or meta position; or when R^1 and X are as above and R^{13} is $NHSO_2CF_3$ or $NHSO_2CH_3$, R^{13} must be ortho;

10

(3) when R^1 is , and X is other than


15

a single bond, then R^{13} must be ortho except when $X = NR^{23}CO$ and R^{13} is $NHSO_2CF_3$ or $NHSO_2CH_3$, then R^{13} must be ortho or meta;

20

(4) when R^1 is $4-CO_2H$ or a salt thereof, R^6 cannot be S-alkyl;
 (5) when R^1 is $4-CO_2H$ or a salt thereof, the substituent on the 4-position of the imidazole cannot be CH_2OH , CH_2OCOCH_3 , or CH_2CO_2H ;

25


(6) when R^1 is , R^6 is not methoxybenzyl;

(7) the R^6 group is not $-CHCH_2CH_2CH_3$ or CH_2OH ;

30


2. A compound of Claim 1 having the formula:

35




wherein


R¹ is -CO₂H; -NHSO₂CF₃; or



5



or



10

R⁶ is alkyl of 3 to 10 carbon atoms, alkenyl of 3 to 10 carbon atoms, alkynyl of 3 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, benzyl substituted on the phenyl ring with up to two groups selected from alkoxy of 1 to 4 carbon atoms, halogen, alkyl of 1 to 4 carbon atoms, and nitro;

15

R⁸ is -(CH₂)_m-tetrazolyl, -(CH₂)_nOR¹¹; -(CH₂)_nO⁰CR¹⁴;


20 -CH=CH(CH₂)_s⁰CR¹⁶, -CH=CH(CH₂)_sCHOR¹⁵;

-(CH₂)_n⁰CR¹⁶; -(CH₂)_nNHCOR¹⁰; -(CH₂)_nNHSO₂R¹⁰;

or -CR¹⁶;

25

R¹³ is -CO₂H, -CO₂R⁹, NHSO₂CF₃; SO₃H; or



30

R¹⁶ is H, alkyl of 1 to 5 carbon atoms, OR¹⁷, or NR¹⁸R¹⁹;

X is carbon-carbon single bond, -CO-, -CON-,

|
R²³

-CH₂CH₂-, -NCO-, -OCH₂-, -CH₂O-, -O-, -SCH₂-,
|
R²³

35

-CH₂S-, -NHCH₂-, -CH₂NH- or -CH=CH-;
or a pharmaceutically acceptable salt thereof.

3. A compound of Claim 2 wherein:


R^2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;

R^6 is alkyl, alkenyl or alkynyl of 3 to 7 carbon atoms;

5

R^7 is heteroaryl selected from 2- and 3-thienyl, 2- and 3-furyl, 2-, 3-, and 4-pyridyl, or p-biphenyl;

10



15

R^8 is $-(CH_2)_mOR^{11}$; $-(CH_2)_mOCR^{14}$; $-CH=CH-CHOR^{15}$;

20

$-(CH_2)_m^0CR^{16}$; $-CH_2NHCOR^{10}$;


$-(CH_2)_m^0NHSO_2R^{10}$; or $-COR^{16}$;

25

R^{10} is CF_3 , alkyl of 1 to 6 carbon atoms or phenyl;

R^{11} is H, or alkyl of 1 to 4 carbon atoms;

R^{13} is CO_2H ; $CO_2CH_2OCOC(CH_3)_3$; $NHSO_2CF_3$



30

R^{14} is H, or alkyl of 1 to 4 carbon atoms;

R^{15} is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;

35

R^{16} is H, alkyl of 1 to 5 carbon atoms; OR¹⁷; or



5 m is 1 to 5;

X = single bond, -O-; -CO-; -NHCO-; or -OCH₂-; or a pharmaceutically acceptable salt thereof.

4. A compound of Claim 3 wherein R¹ is

10 and X is a single bond, or a pharmaceutically suitable salt thereof.

15 5. A pharmaceutical composition comprising a pharmaceutically suitable carrier and a compound of any one of Claims 1 through 4.

20 6. Pharmaceutical composition of Claim 5 which additionally contains a diuretic or a non-steroidal antiinflammatory drug.


25 7. A method of preventing renal failure in a warm blooded animal resulting from administration of a non-steroidal anti-inflammatory drug (NSAID) which comprises administering, stepwise or in physical combination with the NSAID, a compound of any of Claims 1 through 4 in an amount effective to prevent renal failure.

30 8. A method of treating hypertension in a warm blooded animal comprising administering to the animal in an amount effective to lower the animal's blood pressure a compound of any of Claims 1 through 4.

9. Method of Claim 8 wherein a diuretic is administered to the animal prior to or simultaneously with the imidazole compound.

5 10. A method of treating congestive heart failure in a warm-blooded animal comprising administering to the animal a compound of any one of Claims 1 through 4 in an amount effective to correct the hemodynamic burden on the heart to relieve the congestion.

10 11. A process for the preparation of a compound of Claim 1 wherein r is 1 which comprises contacting an imidazole derivative of Formula 1 with a benzyl derivative of Formula 2 in a solvent in the presence of a base for about 1 to about 10 hours at a temperature in the range of about 20°C to the reflux temperature of the solvent to form a benzylimidazole of Formula 3:




wherein each of R¹, R², R³, R⁶, R⁷ and R⁸ is stable under the reaction conditions and is a group as defined in Claim 1 or an intermediate or protected form thereof which can be transformed to such a group and wherein X¹ is halogen, p-toluenesulfonyloxy or methylsulfonyloxy; and thereafter as necessary transforming said intermediate or protected forms of the R groups to R groups as defined in Claim 1.

12. Process of Claim 11 wherein compounds 1 and 2 are contacted in the presence of a base selected from the group consisting of a metal hydride (MH), a metal alkoxide (MOR), sodium carbonate, potassium carbonate, 5 triethylamine and pyridine, in a dipolar aprotic solvent or, where the base is MOR, the solvent can be an alcohol, ROH, where M is lithium, sodium or potassium and R is methyl, ethyl or t-butyl.

10 13. Process of Claim 11 wherein a two-phase solvent system, one an organic phase such as methylene chloride and the other an aqueous phase, is used in the presence of a phase transfer catalyst such as tricaprylmethylammonium chloride.

15

14. Process of Claim 12 wherein: R¹ is



20 X is a carbon-carbon single bond, -CO-, -O-, -S-, or
25 -NH-;

R² and R³ are each independently H, Cl, Br, I, CO₂R¹⁴, F, NO₂, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, aryl or furyl;

R⁶ and R⁷ are as defined in Claim 1;

30 R⁸ is -(CH₂)_nOR¹¹; -(CH₂)_nSR¹⁵; or -(CH₂)_nCN;

R¹¹ is as defined in Claim 1;

R¹³ is CO₂R¹⁴, CN, NO₂, trialkyltin tetrazole, or trityltetrazole; and

R¹⁴ and R¹⁵ are as defined in Claim 1.

15. Process of Claim 14 wherein R¹³ is -CO₂R¹⁴ and the product of Formula 3 is contacted with an alkali in an aqueous alcoholic solvent or with CF₃CO₂H at a temperature in the range of about 20°C to the reflux temperature of the solvent for about 1-24 hours, followed by adjustment of the pH of the mixture to a value in the range of 3 to 7, to convert the product to the corresponding product wherein R¹³ is -CO₂H.

10 16. Process of Claim 15 wherein at least one of R², R³ or R¹³ in Formula 1 is -CO₂R¹⁴ and is converted to -CO₂H.

15 17. Process of Claim 15 wherein R¹⁴ is t-butyl and the reaction is conducted in CF₃CO₂H.

18. Process of Claim 14 wherein R¹³ is -CN and the product of Formula 3 is contacted with (i) a strong acid at reflux temperature of the solvent for about 2-96 hours or (ii) a strong alkali in an alcohol solvent at a temperature in the range of about 20°C and the reflux temperature of the solvent for about 2-96 hours followed by adjustment of the pH to about 3-7, or (iii) sulfuric acid followed by acid or alkali, to convert the product to the corresponding compound wherein R¹³ is -CO₂H.

19. Process of Claim 18 wherein at least one of R², R³ or R¹³ is -CO₂R¹⁴ and is converted to -CO₂H.

30 20. Process of Claim 18 wherein R⁸ is -(CH₂)_nCN and is converted to -(CH₂)_nCO₂H, or is -(CH₂)_nOR¹¹ and is converted to (CH₂)_nOH when R¹³ is converted to -CO₂H.

21. Process of Claim 14 wherein R¹³ is -CN and the product of Formula 3 is contacted with a mixture of equimolar amounts of sodium azide and ammonium chloride in a polar aprotic solvent at a temperature in the
5 range of about 30°C to the reflux temperature of the solvent, for about 1 hour to 10 days, to convert the product to the corresponding compound wherein R¹³ is 5-tetrazolyl.

10 22. Process of Claim 21 wherein R⁸ is -(CH₂)_mCN and is converted to -(CH₂)_m-tetrazolyl when R¹³ is converted to 5-tetrazolyl.

15 23. Process of Claim 14 wherein R¹³ is -CN and the product of Formula 3 is reacted with trialkyltin azide or triaryltin azide followed by acidic or basic hydrolysis to convert the product to the corresponding compound wherein R¹³ is 5-tetrazolyl.

20 24. Process of Claim 14 wherein R¹³ is -CN and the product of Formula 3 is reacted with trialkyltin azide or triaryltin azide to produce a compound of Formula 3 wherein R¹³ is trialkyl or triaryl stanny1 tetrazol-5-y1, the latter compound is reacted with triphenylmethyl chloride to produce a compound of Formula 3 wherein R¹³ is triphenylmethyl-tetrazol-5-y1, and the latter compound is hydrolyzed to produce a compound of Formula 3 wherein R¹³ is 5-tetrazolyl.

25 30 25. Process of Claim 23 wherein R⁸ is -(CH₂)_nCN and is converted to -(CH₂)_m-tetrazolyl when R¹³ is converted to 5-tetrazolyl.


35 26. Process of Claim 14 wherein R¹³ is -NO₂ and the product of Formula 3 is contacted with a reducing

agent to form a second intermediate of Formula 3 in which R¹³ is NH₂, and the latter is contacted with an anhydride (CH₃SO₂)₂O or (CF₃SO₂)₂O or a chloride CH₃SO₂Cl or CF₃SO₂Cl of sulfonic acid in a solvent to 5 produce a compound in which R¹³ is -NHSO₂CH₃ or -NHSO₂CF₃.

27. Process of Claim 26 wherein at least one of R², R³, or R¹³ is -NO₂ and is converted to -NHSO₂CH₃ or 10 -NHSO₂CF₃.

28. Process of Claim 15 or 18 wherein the compound of Formula 3 with R¹³=CO₂H either
15 (a) is contacted with about 1-4 equivalents of thionyl chloride in excess thionyl chloride or another solvent at a temperature in the range of about 20°C to the reflux temperature of the solvent for a period of about 5 minutes to about 2 hours to form an intermediate of Formula 3 wherein R¹³ is COCl, and the
20 latter is contacted with about 2-10 equivalents of hydroxylamine derivative H₂NOR¹² in excess hydroxylamine derivative H₂NOR¹² or other solvent, at a temperature in the range of about 25-80°C for about 2-18 hours, or

25 (b) is contacted the hydroxylamine derivative H₂NOR¹², dicyclohexylcarbodiimide and 1-hydroxybenzotriazole in a solvent at a temperature in the range of about 0-30°C for about 1-24 hours;
30 to provide a compound in which R¹³ is CONHOR¹².

29. Process of Claim 11 wherein: R¹ is

X is a carbon-carbon single bond, -CO-, -O-, -S-, or
 10 -NH-;
 R², R³, R⁶ and R⁷ are as defined in Claim 1;
 and
 R⁸ is (CH₂)_nOR¹¹, (CH₂)_nOCOR¹⁴, (CH₂)_nCH(OH)R¹⁶,
 (CH₂)_nCOR¹⁶ (CH₂)_nCl, (CH₂)_nCN, CHO.

15 30. Process of Claim 29 wherein R⁸ is (CH₂)_nOH
 and the product of Formula 3 is contacted with an
 alcohol R¹¹OH in the anhydrous state in the presence of
 a strong acid or a Lewis acid, followed by
 20 saponification of any CO₂R¹⁴ groups concomitantly
 formed or present in intermediate 3, to form the
 corresponding compound of Formula 3 wherein R⁸ is
 (CH₂)_nOR¹¹ and R¹¹ is not H.

25 31. Process of Claim 29 wherein R⁸ is (CH₂)_nOR¹¹
 and R¹¹ is not H and the product of Formula 3 is
 contacted with an aqueous acidic medium at a
 temperature in the range of about 25°C and the reflux
 temperature of the solvent for a period of about 0.5-24
 30 hours to form the corresponding compound of Formula 3
 wherein R⁸ is (CH₂)_nOH.

32. Process of Claim 29 wherein R⁸ is (CH₂)_nOH
 and the product of Formula 3 is contacted with

(a) a carboxylic acid anhydride $(R^{14}CO)_2O$ or chloride $R^{14}COCl$ in a solvent in presence of a base at a temperature in the range of about $0^{\circ}C$ and the reflux temperature of the solvent for about 0.5-24 hours or

5 (b) a carboxylic acid $R^{14}CO_2H$ under anhydrous conditions in presence of a strong acid or Lewis acid at about 0° - $100^{\circ}C$ for about 0.5 to 24 hours, to form the corresponding compound in which R^8 is $(CH_2)_nOCOR^{14}$.

10 33. Process of Claim 29 wherein R^8 is $(CH_2)_nOCOR^{14}$ and the product of Formula 3 is contacted with aqueous acid or alkali to form the corresponding compound wherein R^8 is $(CH_2)_nOH$.

15 34. Process of Claim 29 wherein R^8 is $(CH_2)_nOH$ and the product of Formula 3 is contacted with an oxidizing agent at a temperature of about 25 - $45^{\circ}C$ for about 1-200 hours to produce a corresponding compound 20 of Formula 3 in which R^8 is $(CH_2)_{n-1}COR^{16}$ and R^{16} is H.

25 35. Process of Claim 29 wherein R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is H and the product of Formula 3 is contacted with an organometallic compound $R^{16}P$ in which P is MgBr or Li in a solvent at a temperature in the range of about $-78^{\circ}C$ to $100^{\circ}C$ for about 0.5-24 hours to form a compound of Formula 3 in which R^8 is $(CH_2)_nCH(OH)R^{16}$ and R^{16} is not H.

30 36. Process of Claim 29 wherein R^8 is $(CH_2)_nCH(OH)R^{16}$ and R^{16} is not H and the product of Formula 3 is contacted with an oxidizing agent in a solvent to form a corresponding compound of Formula 3 in which R^8 is $(CH_2)_nCOR^{16}$ and R^{16} is not H.

37. Process of Claim 29 wherein R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is H and the compound of Formula 3 is contacted with an oxidizing agent in a solvent to form a corresponding compound of Formula 3 in which R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is OH.

38. Process of Claim 29 wherein R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is OH and the compound of Formula 3 is contacted with thionyl chloride in excess or in another solvent at a temperature in the range of about 0°C to the reflux temperature of the solvent for about 5 minutes to about 24 hours to form a corresponding compound of Formula 3 in which R⁸ is (CH₂)_nCOCl followed by contact of the latter with an amine NHR¹⁸R¹⁹ in excess or in a solvent at temperatures in the range of about 0°C and reflux temperature of the solvent for about 5 minutes to about 24 hours to form a corresponding compound of Formula 3 in which R⁸ is (CH₂)_nCONR¹⁸R¹⁹.

39. Process of Claim 29 wherein R⁸ is (CH₂)_nOR¹¹ and R¹¹ is H and the product of Formula 3 is contacted with thionyl chloride in excess or in a solvent at a temperature in the range of about 20°C to the reflux temperature of the solvent for about 0.5-24 hours to form an intermediate compound of Formula 3 in which R⁸ is (CH₂)_nCl.

40. Process of Claim 39 wherein the compound of Formula 3 in which R⁸ is (CH₂)_nCl is contacted with sodium or potassium salt of a mercaptan R¹⁵SH in a solvent at a temperature in the range of about 25-100°C for about 1-24 hours to form a compound of Formula 3 in which R⁸ is (CH₂)_nSR¹⁵.

41. Process of Claim 29 wherein the compound of Formula 3 in which R⁸ is (CH₂)_nCl is contacted with an alkali metal cyanide in a solvent at a temperature in the range of about 20-100°C for about 1-24 hours to form a compound of Formula 3 in which R⁸ is (CH₂)_nCN and the latter compound is hydrolyzed to the corresponding compound of Formula 3 in which R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is OH.

5

10 42. Process of Claim 29 wherein the compound of Formula 3 in which R⁸ is (CH₂)_{n-1}Cl is contacted with the sodium or potassium salt of a dialkyl malonate in a solvent at a temperature in the range of about 20-100°C for about 0.5-24 hours to form a compound of Formula 3

15 in which R⁸ is (CH₂)_{n-1}CH(CO₂alkyl)₂ followed by saponification of the latter with aqueous alkali at a temperature in the range of about 25°C to the reflux temperature of the solvent followed by acidification with mineral acid to form a compound of Formula 3 in which R⁸ is (CH₂)_{n-1}CH(CO₂H)₂ followed by heating the latter to about 120°C or in dilute mineral acid at reflux temperature to form a product of Formula 3 in which R⁸ is (CH₂)_nCOR¹⁶ and R¹⁶ is OH.

20

25 43. Process of Claim 29 wherein R⁸ is -CHO and the compound of Formula 3 is contacted with a methylene phosphorane (C₆H₅)₃P=CH(CH₂)_sCHR¹⁴OR¹⁵ or (C₆H₅)₃P=CH(CH₂)_sCOR¹⁶ in a solvent at a temperature in the range of about 25°C to the reflux temperature of

30 the solvent for about 1-24 hours to form a compound of Formula 3 in which R⁸ is -CH=CH(CH₂)_sCHR¹⁴OR¹⁵ or -CH=CH(CH₂)_sCOR¹⁶, except where R¹⁵ is H and R¹⁶ is OH, and optionally then contacting the compound of Formula 3 in which R⁸ is -CH=CH(CH₂)_sCOR¹⁶ with a reducing

35 agent in a solvent at a temperature of about 0°-25°C

for about 0.5-24 hours to form a product of Formula 3 in which R⁸ is -CH=CH(CH₂)₅CHR¹⁴OH.

44. Process of Claim 29 wherein R⁸ is (CH₂)_nOH
5 and the compound of Formula 3 is contacted with an isocyanate of Formula R¹⁰NCO in a solvent at a temperature in the range of about 25°C to the reflux temperature of the solvent for a period of about 5 minutes to about 24 hours to form a compound of Formula 10 3 in which R⁸ is (CH₂)_nOCONHR¹⁰.

45. Process of Claim 29 wherein the compound in which R⁸ is (CH₂)_nCl is contacted with an amine R¹¹NH₂ in excess amine or another solvent for a period of 15 about 1-24 hours at a temperature in the range of about 0°C to the reflux temperature of the solvent to form an intermediate of Formula 3 in which R⁸ is (CH₂)_nNHR¹¹.


46. Process of Claim 29 in which R⁸ is (CH₂)_nCl
20 and the compound of Formula 3 is contacted with an alkali metal azide in an aprotic solvent at a temperature in the range of about 25-80°C for about 1-24 hours to form a compound of Formula 3 in which R⁸ is (CH₂)_nN₃ and the latter is contacted with a reducing 25 agent to form an intermediate of Formula 3 in which R⁸ is (CH₂)_nNH₂.

47. Process of Claim 45 or 46 in which R⁸ is (CH₂)_nNHR¹¹ or (CH₂)_nNH₂ and the compound of Formula 3 is contacted with a chloroformate of Formula R¹⁰OCOCl or a sulfonyl derivative of Formula R¹⁰SO₂Cl, or (R¹⁰SO₂)₂O in a solvent in the presence of a base at a temperature in the range of about 0°C to the reflux temperature of a solvent for about 5 minutes to about 35

24 hours to form a compound of Formula 3 in which R⁸ is -(CH₂)_nNR¹¹CO₂R¹⁰ or -(CH₂)_nNR¹¹SO₂R¹⁰.

48. Process of Claim 45 or 46 in which the
 5 compound of Formula 3 with R⁸ equal to -(CH₂)_nNHR¹¹ or
 (CH₂)_nNH₂ is contacted with an isocyanate or
 isothiocyanate R¹⁰NCY in a solvent at a temperature in
 the range of about 25°C to the reflux temperature of
 10 the solvent for about 5 minutes to about 24 hours to
 form a compound of the Formula 3 in which R⁸ is
 -(CH₂)_nNR¹¹CYNHR¹⁰.

49. Process of Claim 11 wherein R¹ is NO₂ and R²,
 R³, R⁶, R⁷, and R⁸ are as defined in Claim 34 in which
 15 the compound of Formula 3 wherein R¹ is NO₂ is reduced
 by means of iron and acetic acid, stannous chloride, or
 hydrogen and palladium to a compound of Formula 3
 wherein R¹ is NH₂ and the latter is reacted with an
 appropriate acid anhydride such as phthalic anhydride
 20 or a substituted phthalic anhydride in a solvent or
 with an appropriate acid chloride such as substituted
 anthranilic acid chloride in the presence of aqueous
 alkali or a base or with an appropriately substituted
 25 phthalic or anthranilic acid in the presence of
 dicyclohexylcarbodiimide in a solvent to produce a
 compound of the Formula 3 in which R¹ is




35

and X is NHCO.

50. Process of Claim 11 wherein R¹ is OCH₂C₆H₅, R² and R³ are H and R⁶, R⁷, and R⁸ are as defined in Claim 11 and the resulting compound of Formula 3 with R¹ equal to OCH₂C₆H₅ is contacted with trifluoroacetic acid at reflux temperature for a period of about 0.2-1 hour or with hydrogen and palladium to form the corresponding compound of Formula 3 in which R¹ is OH and the latter is contacted with a base at about 25°C and a suitable benzyl halide of the formula:


10

15



20 to produce the corresponding compound of Formula 3 wherein R¹ is

25



and X is -OCH₂-.

30


51. Process of Claim 11 wherein R⁸ is -CHO, whereby the benzyl derivative of Formula 2 attaches to the imidazole derivative of Formula 1 preferentially at the nitrogen atom adjacent the carbon atom of the imidazole ring to which R⁸ is attached.

52. A process for the preparation of a compound of Claim 1 wherein r is 0 which comprises contacting an imidazole derivative of Formula 1 or its metallic salt with 4-fluoro-1-nitrobenzene in a solvent, in the presence of a base if the free imidazole is used, for 1-10 days at a temperature of 25-150°C to form an N-phenylimidazole followed by elaboration to compounds wherein X=NHC₀ by the process described in Claim 49.

10 53. A process of Claim 29 wherein R⁸ is CHO, and X is a carbon-carbon single bond, and the product of Formula 3 is contacted with an organometallic reagent such as R¹¹MgBr or R¹¹Li in the presence of an anhydrous nonhydroxylc solvent such as ether, THF or dimethoxyethane at -78 to 25°C followed by aqueous work-up followed by acid hydrolysis of any CO₂R¹⁴ groups where R¹⁴ is t-butyl or hydrolysis of any trityl-protected tetrazole groups to form the corresponding compound of Forumula 3 wherein R⁸ is -(CH₂)_{n-1}-CH-R¹¹, where R¹¹ ≠ H.


20 OR¹⁷

25 54. A process for the preparation of the compounds of claim 1 where R⁷ = substituted or unsubstituted biphenyl, phenoxyphenyl, or heteroaryl, characterized in that haloimidazole 237 is coupled with an arylmetal derivative ArM, where M=ZnBr, Me₃Sn, B(OH)₂, etc. in the presence of a transition metal catalyst such as palladium, platinum, nickel, or zirconium, to form an arylimidazole 238:



10 where R¹, R², R³, R⁶, R⁸ and r have the meanings given
in Claim 1, X is Br or I, M is ZnBr, Me₃Sn, B(OH)₂,
etc., and Ar is substituted or unsubstituted
biphenyl, phenoxyphenyl, or heteroaryl.
15 55. A process for the preparation of the

15 55. A process for the preparation of the
compounds of Claim 1 where R⁷=substituted or
unsubstituted biphenylmethyl, phenoxyphenylmethyl, or
heteroaryl methyl characterized in that a haloimidazole
237 is coupled with an arylmethylmetal derivative
20 ArCH₂M' in the presence of a transition metal catalyst
to form an arylmethylimidazole 240:




where R¹, R², R³, R⁶, R⁸ and r have the meanings given in Claim 1, X is Br or I, M' is ZnBr, etc., and Ar is substituted or unsubstituted heteroaryl methyl, biphenyl methyl, phenoxyphenyl methyl.

5

56. A process for the preparation of the compounds of Claim 1 where R⁷=vinyl, alkynyl, substituted alkenyl, or substituted alkynyl characterized in that a haloimidazole 237 is coupled with an 1-alkenylmetal or an 1-alkynylmetal derivative (AM), or an 1-alkene, or an 1-alkyne (AH) in the presence of a transition metal catalyst to form a 1-alkenyl- or 1-alkynylimidazole 241:

15




25

30

where R¹, R², R³, R⁶, R⁸ and r have the meanings given in Claim 1, X is Br or I, M is a metal, A is vinyl, CH=CH(CH₂)_xAr, C≡C(CH₂)_yCH₃, C≡C(CH₂)_zPh', or C≡C(CH₂)_xAr, Ph' is phenyl or substituted phenyl,


and Ar is substituted or unsubstituted biphenyl, phenoxyphenyl or heteroaryl, $x=0-8$, $y=0-7$ and $z=0-4$.

5 57. A process for the preparation of the
compounds of claim 1 where R^7 =vinyl or substituted
alkenyl characterized in that imidazole aldehyde 253 is
reacted with methylenetriphenylphosphorane or a
10 substituted methylenetriphenylphosphorane to form a
vinylimidazole or a substituted alkenylimidazole 254:



30 where R^1 , R^2 , R^3 , R^6 , R^8 and r have the meanings given
in Claim 1, Ar is substituted or unsubstituted
biphenyl, phenoxyphenyl or heteroaryl, and
 $u + v = 0$ to 8.

58. A process for the preparation of the compounds of Formula I wherein R⁷ is -S(O)_r-heteroaryl, -S-(O)_r-biphenylyl, -S-(O)_r-phenoxyphenyl, -S-tetrazole, -S(O)_rR¹⁷, -NR¹⁸R¹⁹, -NR¹⁸-heteroaryl, -NR¹⁸-phenyl, -NR¹⁸-biphenylyl, -NR¹⁸phenoxyphenyl, -N-phthalimido, -NH-SO₂-phenoxyphenyl, -NH-SO₂-heteroaryl, -NH-SO₂-biphenylyl, -NH-SO₂-R¹⁷, and -S-(C=O)-R¹⁷, N-imidazolyl, N-1,2,3-triazolyl, and N-1,2,4-triazolyl, characterized in that imidazole containing compounds 5 255 substituted with an electron withdrawing group E are reacted with nucleophiles in a suitable solvent at room temperature to the reflux temperature of the solvent resulting in an aromatic substitution reaction whereby the leaving group X is substituted with a 10 nucleophile Nu such as sulfur or nitrogen to produce 15 compounds of structure 256:



30

35

INTERNATIONAL SEARCH REPORT

International Application No PCT/US 90/03683

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC
 IPC5: C 07 D 233/64, 233/90, 403/10, 405/14

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System	Classification Symbols
IPC5	C 07 D

Documentation Searched other than Minimum Documentation
 to the Extent that such Documents are Included in Fields Searched⁸

III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP, A2, 0324377 (E.I. DU PONT DE NEMOURS AND COMPANY) 19 July 1989, see especially pages 213-223	1-2,5-6, 11-58
A	---	3-4
X	EP, A2, 0253310 (E.I. DU PONT DE NEMOURS AND COMPANY) 20 January 1988, see especially pages 277-285	1-2,5-6, 11-58
A	---	3-4

* Special categories of cited documents:¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

4th October 1990

Date of Mailing of this International Search Report

24 OCT 1990

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

Mme N. KUIPER

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET**V. OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹**

This International search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. Claim numbers 7-10 because they relate to subject matter not required to be searched by this Authority, namely:

A method for treatment of the human or animal body by therapy.
See PCT Rule 39.1(iv)

2. Claim numbers....., because they relate to parts of the International application that do not comply with the prescribed requirements to such an extent that no meaningful International search can be carried out, specifically:

3. Claim numbers....., because they are dependent claims and are not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This International Searching Authority found multiple inventions in this international application as follows:

1. As all required additional search fees were timely paid by the applicant, this International search report covers all searchable claims of the International application.

2. As only some of the required additional search fees were timely paid by the applicant, this International search report covers only those claims of the International application for which fees were paid, specifically claims:

3. No required additional search fees were timely paid by the applicant. Consequently, this International search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

The additional search fees were accompanied by applicant's protest.

No protest accompanied the payment of additional search fees.

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.PCT/US 90/03683**

SA 38709

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on **28/08/90**
The European Patent office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A2- 0324377	19/07/89	AU-D- WO-A- 2777189 89/06233	13/07/89 13/07/89
EP-A2- 0253310	20/01/88	AU-B- AU-D- 599396 JP-A- 7559687 63023868	19/07/90 21/01/88 01/02/88

For more details about this annex : see Official Journal of the European patent office, No. 12/82